[
  {
    "statement_id": "RN101",
    "patent_id": "11434523",
    "claim": "A system and method for detecting rare mutations and copy number variations in cell-free polynucleotides extracted from bodily fluids, combining sample preparation, sequencing of cell-free polynucleotides, and bioinformatics analysis against a reference database of disease-specific rare mutation and copy number variation profiles to enable genetic profiling of disease states.",
    "title": "Systems and methods to detect rare mutations and copy number variation",
    "abstract": "The present disclosure provides a system and method for the detection of rare mutations and copy number variations in cell free polynucleotides. Generally, the systems and methods comprise sample preparation, or the extraction and isolation of cell free polynucleotide sequences from a bodily fluid; subsequent sequencing of cell free polynucleotides by techniques known in the art; and application of bioinformatics tools to detect rare mutations and copy number variations as compared to a reference. The systems and methods also may contain a database or collection of different rare mutations or copy number variation profiles of different diseases, to be used as additional references in aiding detection of rare mutations, copy number variation profiling or general genetic profiling of a disease.",
    "domain": "C12"
  },
  {
    "statement_id": "RN102",
    "patent_id": "8084207",
    "claim": "Compositions and methods for identifying human papillomavirus (HPV) by combining nucleic acid amplification with molecular mass or base composition analysis to enable precise identification of HPV types from biological samples.",
    "title": "Compositions for use in identification of papillomavirus",
    "abstract": "The present invention relates generally to identification of HPV, and provides methods, compositions and kits useful for this purpose when combined, for example, with molecular mass or base composition analysis.",
    "domain": "C12"
  },
  {
    "statement_id": "RN103",
    "patent_id": "11472849",
    "claim": "A method of assembling transcription activator-like effector (TALE) repeat domain arrays by sequentially ligating nucleic acid fragments encoding TALE repeat domains through compatible ligatable ends created by specific enzymes, wherein the ligated nucleic acid product is linked to a solid support, enabling construction of a polypeptide comprising multiple TALE repeat domain sets.",
    "title": "Methods of transcription activator like effector assembly",
    "abstract": "The disclosure describes methods that include providing a first nucleic acid having a sequence encoding a first set comprising one or more transcription activator-like effector (TALE) repeat domains and/or one or more portions of one or more TALE repeat domains; contacting the first nucleic acid with a first enzyme, wherein the first enzyme creates a first ligatable end; providing a second nucleic acid having a sequence encoding a second set comprising one or more TALE repeat domains and/or one or more portions of one or more TALE repeat domains; contacting the second nucleic acid with a second enzyme, wherein the second enzyme creates a second ligatable end, and wherein the first and second ligatable ends are compatible; and ligating the first and second nucleic acids through the first and second ligatable ends to produce a first ligated nucleic acid, wherein the first ligated nucleic acid is linked to a solid support, and wherein the first ligated nucleic acid encodes a polypeptide comprising said first and second sets.",
    "domain": "C12"
  },
  {
    "statement_id": "RN104",
    "patent_id": "9186643",
    "claim": "A method for in vitro evolution that compartmentalizes individual genetic elements into microcapsules and sorts those expressing a gene product with desired activity, where at least one of the compartmentalization or sorting steps is controlled by a microfluidic system, enabling iterative mutagenesis and selection of nucleic acids and proteins.",
    "title": "In vitro evolution in microfluidic systems",
    "abstract": "The invention describes a method for isolating one or more genetic elements encoding a gene product having a desired activity, comprising the steps of: (a) compartmentalizing genetic elements into microcapsules; and (b) sorting the genetic elements which express the gene product having the desired activity; wherein at least one step is under microfluidic control. The invention enables the in vitro evolution of nucleic acids and proteins by repeated mutagenesis and iterative applications of the method of the invention.",
    "domain": "C12"
  },
  {
    "statement_id": "RN105",
    "patent_id": "11519035",
    "claim": "A method for simultaneously amplifying multiple nucleic acid target loci in a single reaction volume using a library of primers designed to minimize formation of primer dimers and non-target amplicons, wherein the primer library is selected through a computational process that evaluates and excludes primer pairs with cross-reactivity or self-complementarity above defined thresholds.",
    "title": "Methods for simultaneous amplification of target loci",
    "abstract": "The invention provides methods for simultaneously amplifying multiple nucleic acid regions of interest in one reaction volume as well as methods for selecting a library of primers for use in such amplification methods. The invention also provides library of primers with desirable characteristics, such as minimal formation of amplified primer dimers or other non-target amplicons.",
    "domain": "C12"
  },
  {
    "statement_id": "RN106",
    "patent_id": "10414789",
    "claim": "Cyclic purine dinucleotide (CDN) compositions comprising substantially pure Rp,Rp or Rp,Sp thiophosphate diastereomers that activate the STING (Stimulator of Interferon Genes) cytoplasmic receptor to induce STING-dependent TBK1 activation, wherein the defined stereochemistry at the phosphorothioate linkages distinguishes these CDN immune stimulators from mixed diastereomeric preparations.",
    "title": "Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use",
    "abstract": "It is an object of the present invention to provide novel and highly active cyclic-di-nucleotide (CDN) immune stimulators that activates DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides that induce STING-dependent TBK1 activation, wherein the cyclic purine dinuclotides present in the composition are substantially pure Rp,Rp or Rp,Sp stereoisomers, and particularly substantially pure Rp,Rp, or RpSp CDN thiophosphate diastereomers.",
    "domain": "C12"
  },
  {
    "statement_id": "RN107",
    "patent_id": "6395966",
    "claim": "A fertile transgenic maize plant containing an integrated phosphinothricin acetyltransferase (PAT) gene at a specific chromosomal locus where the integration event is correlated with increased yield, and a method of transferring this increased yield phenotype to other maize lines by crossing with the transgenic plant.",
    "title": "Fertile transgenic maize plants containing a gene encoding the pat protein",
    "abstract": "The present invention provides methods for increasing yield in plants by introducing a gene encoding phosphinothricin acetyltransferase. The invention further involves a method of transferring said increased yield phenotype to other lines of plants by crossing. A maize transformant is identified in which the phosphinothricin acetyltransferase gene integration event is correlated with increased yield.",
    "domain": "C12"
  },
  {
    "statement_id": "RN108",
    "patent_id": "9376699",
    "claim": "A method for targeted modification of endogenous genes in eukaryotic cells using large DNA targeting vectors (LTVECs) derived from cloned genomic DNA fragments larger than those used in conventional homologous recombination approaches, combined with a quantitative detection method to identify correctly targeted cells for generating genetically modified organisms.",
    "title": "Methods of producing hybrid antibodies",
    "abstract": "A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.",
    "domain": "C12"
  },
  {
    "statement_id": "RN109",
    "patent_id": "8535889",
    "claim": "A droplet-based digital PCR method that forms sample droplets containing on average a single target nucleic acid, amplifies the target within droplets, and selectively excludes droplets containing both amplicon from the target and amplicon from a variant of the target, thereby enabling analysis of target amplicons independently from variant amplicons.",
    "title": "Digital analyte analysis",
    "abstract": "The invention generally relates to droplet based digital PCR and methods for analyzing a target nucleic acid using the same. In certain embodiments, methods of the invention involve forming sample droplets containing, on average, a single target nucleic acid, amplifying the target in the droplets, excluding droplets containing amplicon from the target and amplicon from a variant of the target, and analyzing target amplicons.",
    "domain": "C12"
  },
  {
    "statement_id": "RN110",
    "patent_id": "10061889",
    "claim": "A method for determining fetal chromosome copy number non-invasively by analyzing SNP microarray data from maternal serum containing mixed fetal and maternal DNA together with parental genomic data, wherein the combined analysis of fetal-maternal mixed genetic material and both biological parents' genotypes enables ploidy calling for clinical prenatal diagnosis decisions.",
    "title": "Methods for non-invasive prenatal ploidy calling",
    "abstract": "Disclosed herein are methods for determining the copy number of a chromosome in a fetus in the context of non-invasive prenatal diagnosis. In an embodiment, the measured genetic data from a sample of genetic material that contains both fetal DNA and maternal DNA is analyzed, along with the genetic data from the biological parents of the fetus, and the copy number of the chromosome of interest is determined. In an embodiment, the maternal serum is measured using a single-nucleotide polymorphism (SNP) microarray, along with parental genomic data, and the determination of the chromosome copy number is used to make clinical decisions pertaining to the fetus.",
    "domain": "C12"
  },
  {
    "statement_id": "RN111",
    "patent_id": "10196700",
    "claim": "A device comprising multivolume analysis regions of different discrete volumes that supports nucleic acid amplification and detection, enabling digital quantification of nucleic acids or other analytes by distributing a sample across multiple partitions of varying sizes to extend the dynamic range of detection beyond what is achievable with uniform-volume partitioning.",
    "title": "Multivolume devices, kits and related methods for quantification and detection of nucleic acids and other analytes",
    "abstract": "Provided are devices comprising multivolume analysis regions, the devices being capable of supporting amplification, detection, and other processes. Also provided are related methods of detecting or estimating the presence nucleic acids, viral levels, and other biological markers of interest.",
    "domain": "C12"
  },
  {
    "statement_id": "RN112",
    "patent_id": "7838210",
    "claim": "A sperm cell suspension formulation comprising a motility inhibitor that preserves cell viability during flow cytometric sorting processes, resulting in post-sort compositions with increased numbers of viable or motile sperm enriched for either X or Y chromosome-bearing cells.",
    "title": "Sperm suspensions for sorting into X or Y chromosome-bearing enriched populations",
    "abstract": "Sperm cell suspensions comprising a motility inhibitor are disclosed. The cells contained in such suspensions tend to have a greater capacity for enduring the various process steps typically associated with the sorting of sperm cells into gender enriched populations, thereby resulting in post-sort compositions with an increased number of viable or motile sperm. Processes for forming such cell suspensions, as well as processes for staining sperm cells, are also disclosed.",
    "domain": "C12"
  },
  {
    "statement_id": "RN113",
    "patent_id": "8114851",
    "claim": "A short double-stranded RNA of less than 49 nucleotides in length, having a nucleotide sequence complementary to at least a part of a target gene, used to specifically inhibit expression of that target gene in mammals for treating diseases including cancer, viral diseases, or neurodegenerative diseases.",
    "title": "Method and medicament for inhibiting the expression of a given gene",
    "abstract": "The present invention relates to the specific inhibition of expression of a target gene in mammals using a short double stranded RNA. The dsRNA is less than 49 nucleotides in length and has a nucleotide sequence which is complementary to at least a part of the target gene. The dsRNAs of the present invention are useful for treating diseases, for example, cancer, viral diseases or neurodegenerative diseases.",
    "domain": "C12"
  },
  {
    "statement_id": "RN114",
    "patent_id": "11473062",
    "claim": "A non-human donor animal (swine) genetically engineered to lack wild-type surface glycan epitopes and having its swine leukocyte antigen (SLA) sequences replaced with synthetic nucleotides based on a specific human recipient's HLA reference sequence, thereby generating personalized, immunologically matched transplantable cells, tissues, and organs tailored to an individual human recipient.",
    "title": "Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to same",
    "abstract": "A biological system for generating and preserving a repository of personalized, humanized transplantable cells, tissues, and organs for transplantation, wherein the biological system is biologically active and metabolically active, the biological system having genetically reprogrammed cells, tissues, and organs in a non-human animal for transplantation into a human recipient, wherein the non-human animal does not present one or more surface glycan epitopes and specific sequences from the wild-type swine's SLA is replaced with a synthetic nucleotides based on a human captured reference sequence from a human recipient's HLA.",
    "domain": "C12"
  },
  {
    "statement_id": "RN115",
    "patent_id": "10785966",
    "claim": "A genetically modified mouse engineered to express human M-CSF (macrophage colony-stimulating factor) protein, wherein the mouse is engrafted with human hematopoietic cells to create a humanized immune system model that supports human hematopoietic cell development and activity in vivo.",
    "title": "Humanized M-CSF mice",
    "abstract": "Genetically modified mice comprising a nucleic acid sequence encoding a human M-CSF protein are provided. Also provided are genetically modified mice comprising a nucleic acid sequence encoding a human M-CSF protein that have been engrafted with human cells such as human hematopoietic cells, and methods for making such engrafted mice. These mice find use in a number of applications, such as in modeling human immune disease and pathogen infection; in in vivo screens for agents that modulate hematopoietic cell development and/or activity, e.g. in a healthy or a diseased state; in in vivo screens for agents that are toxic to hematopoietic cells; in in vivo screens for agents that prevent against, mitigate, or reverse the toxic effects of toxic agents on hematopoietic cells; in in vivo screens of human hematopoietic cells from an individual to predict the responsiveness of an individual to a disease therapy, etc.",
    "domain": "C12"
  },
  {
    "statement_id": "RN116",
    "patent_id": "11408031",
    "claim": "A non-invasive prenatal paternity testing method that determines biological paternity by extracting fetal DNA from maternal plasma and comparing its genetic fingerprint to that of an alleged father using an informatics-based approach, while accounting for maternal genetic contributions through separate maternal genetic measurements.",
    "title": "Methods for non-invasive prenatal paternity testing",
    "abstract": "Methods for non-invasive prenatal paternity testing are disclosed herein. The method uses genetic measurements made on plasma taken from a pregnant mother, along with genetic measurements of the alleged father, and genetic measurements of the mother, to determine whether or not the alleged father is the biological father of the fetus. This is accomplished by way of an informatics based method that can compare the genetic fingerprint of the fetal DNA found in maternal plasma to the genetic fingerprint of the alleged father.",
    "domain": "C12"
  },
  {
    "statement_id": "RN117",
    "patent_id": "10149897",
    "claim": "A scaffold device in which a bioactive composition is incorporated into or coated onto a scaffold composition to actively recruit host cells into the scaffold, modify the recruited cells, and control the egress of those resident cells or their progeny from the material, thereby mediating in vivo cell programming and release without requiring ex vivo cell manipulation.",
    "title": "Scaffolds for cell transplantation",
    "abstract": "A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated into or coated onto the scaffold composition such that the scaffold composition and/or a bioactive composition controls egress of a resident cell or progeny thereof. The devices mediate active recruitment, modification, and release of host cells from the material.",
    "domain": "C12"
  },
  {
    "statement_id": "RN118",
    "patent_id": "10221436",
    "claim": "A method for preparing a nucleic acid sequencing library by amplifying a template nucleic acid using dNTPs combined with dUTP and random hexamer primers to incorporate occasional uracil bases into complementary strands, then treating with a dUTP-excising enzyme to introduce nicks at uracil sites, in the presence of bead-bound oligonucleotide adapter sequences.",
    "title": "Processes and systems for preparation of nucleic acid sequencing libraries and libraries prepared using same",
    "abstract": "This disclosure provides methods for preparing a sequencing library including the steps of providing a template nucleic acid sequence, dNTPs, dUTP, a primer, a polymerase, a dUTP excising enzyme, and a plurality of beads including oligonucleotide adapter sequence segments; amplifying the template nucleic acid with the polymerase, dNTPs, dUTP and random hexamer to provide a complementary nucleic acid sequence including occasional dUTPs; and excising the incorporated dUTPs with the dUTP excising enzyme to provide nicks in the complementary nucleic acid sequence to provide a sequencing library.",
    "domain": "C12"
  },
  {
    "statement_id": "RN119",
    "patent_id": "9821011",
    "claim": "T cells engineered to be deficient in T-cell receptor (TCR) expression while simultaneously expressing a functional non-TCR receptor, wherein the TCR deficiency prevents graft-versus-host disease and the non-TCR receptor redirects cytotoxic activity toward a target disease.",
    "title": "T-cell receptor-deficient T cell compositions",
    "abstract": "The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same.",
    "domain": "C12"
  },
  {
    "statement_id": "RN120",
    "patent_id": "6403957",
    "claim": "A method for synthesizing nucleic acid or peptide sequences on a substrate surface by selectively exposing regions bearing photoremovable protecting groups to light to activate those regions, then coupling monomers that also carry photoremovable protecting groups, and iteratively repeating this light-directed deprotection and monomer addition process to build up combinatorial arrays of sequences of defined length.",
    "title": "Nucleic acid reading and analysis system",
    "abstract": "A method and apparatus for preparation of a substrate containing a plurality of sequences. Photoremovable groups are attached to a surface of a substrate. Selected regions of the substrate are exposed to light so as to activate the selected areas. A monomer, also containing a photoremovable group; is provided to the substrate to bind at the selected areas. The process is repeated using a variety of monomers such as amino acids until sequences of a desired length are obtained. Detection methods and apparatus are also disclosed.",
    "domain": "C12"
  },
  {
    "statement_id": "RN121",
    "patent_id": "11400072",
    "claim": "Use of INT131, a selective PPARγ agonist, alone or in combination with vitamin E, to treat nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and/or lipodystrophic syndromes associated with insulin resistance, where the selective PPARγ partial agonism distinguishes it from full PPARγ agonists such as thiazolidinediones.",
    "title": "Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy",
    "abstract": "The present invention relates to methods for treating a disease associated with insulin resistance selected from a nonalcoholic fatty liver disease (NAFLD) and its sequelae, a lipodystrophic syndrome or a combination thereof with the selective PPARγ agonist, INT131 and optionally vitamin E or compositions thereof. NAFLDs that may be treated with methods and compositions of the present invention include, but are not limited to, simple nonalcoholic fatty liver and nonalcoholic steatohepatitis (NASH). Lipodystrophic syndromes that may be treated with the methods and compositions of the present invention include, but are not limited to, generalized lipodystrophy including congenital generalized lipodystrophy and acquired generalized lipodystrophy and/or partial lipodystrophy, including congenital partial lipodystrophy and acquired partial lipodystrophy, all of which may or may not include hyperlipidemia and/or hyperglycemia and may or may not include NAFLD.",
    "domain": "C12"
  },
  {
    "statement_id": "RN122",
    "patent_id": "9932572",
    "claim": "A modified Caspase-9 polypeptide engineered to have reduced basal apoptotic activity in the absence of a chemical inducer while retaining inducible apoptotic activity upon inducer addition, for use as a controllable safety switch in adoptive cell therapy applications.",
    "title": "Modified Caspase polypeptides and uses thereof",
    "abstract": "The technology relates in part to compositions comprising modified Caspase-9 polypeptides, compositions comprising nucleic acids coding for modified Caspase-9 polypeptides, chimeric modified Caspase-9 polypeptides, and methods of use thereof, including methods for cell therapy. Methods for cell therapy include modifying transfused cells to express an inducible modified Caspase-9 protein, with reduced basal activity in the absence of the inducer.",
    "domain": "C12"
  },
  {
    "statement_id": "RN123",
    "patent_id": "10522242",
    "claim": "A method for determining fetal chromosome copy number non-invasively by analyzing SNP microarray data from maternal serum containing mixed fetal and maternal DNA in combination with parental genomic data, wherein the allelic distribution patterns at single-nucleotide polymorphisms are used to distinguish fetal ploidy status from the maternal background signal.",
    "title": "Methods for non-invasive prenatal ploidy calling",
    "abstract": "Disclosed herein are methods for determining the copy number of a chromosome in a fetus in the context of non-invasive prenatal diagnosis. In an embodiment, the measured genetic data from a sample of genetic material that contains both fetal DNA and maternal DNA is analyzed, along with the genetic data from the biological parents of the fetus, and the copy number of the chromosome of interest is determined. In an embodiment, the maternal serum is measured using a single-nucleotide polymorphism (SNP) microarray, along with parental genomic data, and the determination of the chromosome copy number is used to make clinical decisions pertaining to the fetus.",
    "domain": "C12"
  },
  {
    "statement_id": "RN124",
    "patent_id": "10061890",
    "claim": "A method for determining fetal chromosome copy number non-invasively by analyzing SNP microarray data from maternal serum containing mixed fetal and maternal DNA together with parental genomic data, wherein the combined analysis of SNP allele distributions from both biological parents and the mixed maternal-fetal sample enables ploidy calling for clinical decision-making.",
    "title": "Methods for non-invasive prenatal ploidy calling",
    "abstract": "Disclosed herein are methods for determining the copy number of a chromosome in a fetus in the context of non-invasive prenatal diagnosis. In an embodiment, the measured genetic data from a sample of genetic material that contains both fetal DNA and maternal DNA is analyzed, along with the genetic data from the biological parents of the fetus, and the copy number of the chromosome of interest is determined. In an embodiment, the maternal serum is measured using a single-nucleotide polymorphism (SNP) microarray, along with parental genomic data, and the determination of the chromosome copy number is used to make clinical decisions pertaining to the fetus.",
    "domain": "C12"
  },
  {
    "statement_id": "RN125",
    "patent_id": "10149905",
    "claim": "An oligonucleotide adjuvant with antitumor activity comprising 2-4 CpG motifs (5'-X1CpGX2-3') within a 14-32 nucleotide sequence, wherein the nucleic acids at both the 3' and 5' termini are S-type (stereospecific) nucleotides connected by phosphorothioate linkages, the 3' end side of at least two CpG motifs contains phosphorothioate linkages, and the oligonucleotide contains at least one nucleotide lacking phosphorothioate modification, creating a chimeric backbone with defined stereochemistry.",
    "title": "Chiral nucleic acid adjuvant having antitumor effect and antitumor agent",
    "abstract": "SummaryProblemThe purpose of the present invention is to provide: a chiral nucleic acid adjuvant having anti-tumor activity; and an anti-tumor agent.SolutionThe present invention relates to an adjuvant for anti-tumor agent, wherein the adjuvant comprises oligonucleotides which comprise two to four CpG motif each represented by 5′-X1CpGX2-3′ and has a length of 14 to 32 nucleotides, wherein a nucleic acid at 3′ end side of at least two CpG motifs is connected by phosphorothioate linkage,wherein each nucleic acid at 3′ end and 5′ end of the oligonucleotide is S type nucleic acid connected by phosphorothioate linkage, and wherein the oligonucleotide comprises at least one nucleic acid without phosphorothioate modification. The present invention relates to an anti-tumor agent containing its adjuvant.",
    "domain": "C12"
  },
  {
    "statement_id": "RN126",
    "patent_id": "10041093",
    "claim": "A non-naturally occurring microbial organism engineered with a muconate biosynthetic pathway comprising exogenous nucleic acids encoding specific enzymes—including beta-ketoadipyl-CoA hydrolase, muconolactone isomerase, muconate cycloisomerase, and muconate cis/trans isomerase among others—that enable biological production of muconic acid (muconate), which can subsequently be chemically converted to terephthalic acid via Diels-Alder cycloaddition with ethylene followed by oxidation, yielding a semi-synthetic route to a key polymer precursor.",
    "title": "Semi-synthetic terephthalic acid via microorganisms that produce muconic acid",
    "abstract": "The invention provides a non-naturally occurring microbial organism having a muconate pathway having at least one exogenous nucleic acid encoding a muconate pathway enzyme expressed in a sufficient amount to produce muconate. The muconate pathway including an enzyme selected from the group consisting of a beta-ketothiolase, a beta-ketoadipyl-CoA hydrolase, a beta-ketoadipyl-CoA transferase, a beta-ketoadipyl-CoA ligase, a 2-fumarylacetate reductase, a 2-fumarylacetate dehydrogenase, a trans-3-hydroxy-4-hexendioate dehydratase, a 2-fumarylacetate aminotransferase, a 2-fumarylacetate aminating oxidoreductase, a trans-3-amino-4-hexenoate deaminase, a beta-ketoadipate enol-lactone hydrolase, a muconolactone isomerase, a muconate cycloisomerase, a beta-ketoadipyl-CoA dehydrogenase, a 3-hydroxyadipyl-CoA dehydratase, a 2,3-dehydroadipyl-CoA transferase, a 2,3-dehydroadipyl-CoA hydrolase, a 2,3-dehydroadipyl-CoA ligase, a muconate reductase, a 2-maleylacetate reductase, a 2-maleylacetate dehydrogenase, a cis-3-hydroxy-4-hexendioate dehydratase, a 2-maleylacetate aminoatransferase, a 2-maleylacetate aminating oxidoreductase, a cis-3-amino-4-hexendioate deaminase, and a muconate cis/trans isomerase. Other muconate pathway enzymes also are provided. Additionally provided are methods of producing muconate.",
    "domain": "C12"
  },
  {
    "statement_id": "RN127",
    "patent_id": "10894977",
    "claim": "A template composition comprising a diverse plurality of synthetic oligonucleotide templates in substantially equimolar amounts that serve as a calibration standard for measuring and correcting differential amplification efficiencies among multiplexed PCR primer sets targeting rearranged T cell receptor or immunoglobulin gene sequences, enabling bias correction in quantitative high-throughput sequencing of lymphoid cell DNA.",
    "title": "Compositions and methods for measuring and calibrating amplification bias in multiplexed PCR reactions",
    "abstract": "Compositions and methods are described for standardizing the DNA amplification efficiencies of a highly heterogeneous set of oligonucleotide primers as may typically be used to amplify a heterogeneous set of DNA templates that contains rearranged lymphoid cell DNA encoding T cell receptors (TCR) or immunoglobulins (IG). The presently disclosed embodiments are useful to overcome undesirable bias in the utilization of a subset of amplification primers, which leads to imprecision in multiplexed high throughput sequencing of amplification products to quantify unique TCR or Ig encoding genomes in a sample. Provided is a template composition comprising a diverse plurality of template oligonucleotides in substantially equimolar amounts, for use as a calibration standard for amplification primer sets. Also provided are methods for identifying and correcting biased primer efficiency during amplification.",
    "domain": "C12"
  },
  {
    "statement_id": "RN128",
    "patent_id": "8691730",
    "claim": "A synthetic antibody library designed by rational analysis of public human antibody sequence databases to replicate the preimmune repertoire, wherein the library incorporates directed sequence diversity and directed length diversity in complementarity-determining regions rather than random mutagenesis.",
    "title": "Rationally designed, synthetic antibody libraries and uses therefor",
    "abstract": "The present invention overcomes the inadequacies inherent in the known methods for generating libraries of antibody-encoding polynucleotides by specifically designing the libraries with directed sequence and length diversity. The libraries are designed to reflect the preimmune repertoire naturally created by the human immune system and are based on rational design informed by examination of publicly available databases of human antibody sequences.",
    "domain": "C12"
  },
  {
    "statement_id": "RN129",
    "patent_id": "9795301",
    "claim": "An optical coherence tomography system that performs spectral analysis by interfering backscattered radiation from a sample structure with reference radiation to generate spectroscopic data, and then computationally reduces scattering effects within that spectroscopic data to extract tissue-specific spectral characteristics for classifying tissue type.",
    "title": "Apparatus, systems, methods and computer-accessible medium for spectral analysis of optical coherence tomography images",
    "abstract": "According to an exemplary embodiment of the present disclosure, apparatus and method can be provided for generating information for at least one structure. For example, using at least one first arrangement, it is possible to receive at least one first radiation from the at least one structure and at least one second radiation from a reference, and interfere the first and second radiations to generate at least one third radiation. Further, with at least one second arrangement, it is possible to generate spectroscopic data as a function of the at least one third radiation, and reduce at least one scattering effect in the spectroscopic data to generate the information. In addition or as an alternative, according to a further exemplary embodiment of the present disclosure, it is possible to classify a type of the structure based on the spectroscopic data to generate the information.",
    "domain": "C12"
  },
  {
    "statement_id": "RN130",
    "patent_id": "10011850",
    "claim": "RNA-guided FokI nucleases (RFNs) comprising FokI nuclease domain fused to catalytically inactive dCas9 (or Cas9) require dimerization of two RFN monomers guided by paired sgRNAs to cleave DNA, thereby increasing genome editing specificity by reducing off-target cleavage that occurs when CRISPR-Cas nucleases tolerate up to five mismatches.",
    "title": "Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing",
    "abstract": "Many studies have shown that CRISPR-Cas nucleases can tolerate up to five mismatches and still cleave; it is hard to predict the effects of any given single or combination of mismatches on activity. Taken together, these nucleases can show significant off-target effects but it can be challenging to predict these sites. Described herein are methods for increasing the specificity of genome editing using the CRISPR/Cas system, e.g., using RNA-guided Foki Nucleases (RFNs), e.g., Fokl-Cas9 or Foki-dCas9-based fusion proteins.",
    "domain": "C12"
  },
  {
    "statement_id": "RN131",
    "patent_id": "8551773",
    "claim": "A self-inactivating HIV-derived lentiviral vector comprising the EF1α promoter and a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) configured for high-efficiency transgene expression in human hematopoietic stem cells and their blood cell derivatives for gene therapy of lympho-hematological disorders.",
    "title": "Methods and compositions relating to improved lentiviral vectors and their applications",
    "abstract": "The present invention provides HIV-derived lentivectors which are safe, highly efficient, and very potent for expressing transgenes for human gene therapy, especially, in human hematopoietic progenitor cells as well as in all other blood cell derivatives. The lentiviral vectors comprise a self-inactivating configuration for biosafety and promoters such as the EF1α promoter as one example. Additional promoters are also described. The vectors can also comprise additional transcription enhancing elements such as the wood chuck hepatitis virus post-transcriptional regulatory element. These vectors therefore provide useful tools for genetic treatments such as inherited and acquired lympho-hematological disorders, gene-therapies for cancers especially the hematological cancers, as well as for the study of hematopoiesis via lentivector-mediated modification of human HSCs.",
    "domain": "C12"
  },
  {
    "statement_id": "RN132",
    "patent_id": "6025545",
    "claim": "Stable genetic transformation of maize cells is achieved by introducing the Streptomyces bar gene into embryogenic maize suspension culture cells via microprojectile bombardment, followed by selection of transformed cells using the herbicide bialaphos, and subsequent regeneration of fertile transgenic maize plants from the transformed cells.",
    "title": "Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof",
    "abstract": "This invention relates to a reproducible system for the production of stable, genetically transformed maize cells, and to methods of selecting cells that have been transformed. One method of selection disclosed employs the Streptomyces bar gene introduced by microprojectile bombardment into embryogenic maize cells which were grown in suspension cultures, followed by exposure to the herbicide bialaphos. The methods of achieving stables transformation disclosed herein include tissue culture methods and media, methods for the bombardment of recipient cells with the desired transforming DNA, and methods of growing fertile plants from the transformed cells. This invention also relates to the transformed cells and seeds and to the fertile plants grown from the transformed cells and to their pollen.",
    "domain": "C12"
  },
  {
    "statement_id": "RN133",
    "patent_id": "11096997",
    "claim": "A scaffold device incorporating or coated with a bioactive composition that actively recruits host cells into the scaffold, modifies them in situ, and controls the egress of the resident cells or their progeny back into the host, enabling cell transplantation without prior ex vivo cell manipulation.",
    "title": "Scaffolds for cell transplantation",
    "abstract": "A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated into or coated onto the scaffold composition such that the scaffold composition and/or a bioactive composition controls egress of a resident cell or progeny thereof. The devices mediate active recruitment, modification, and release of host cells from the material.",
    "domain": "C12"
  },
  {
    "statement_id": "RN134",
    "patent_id": "10251377",
    "claim": "A transgenic non-human vertebrate engineered to express fully human antibodies comprising both human variable and human constant regions, wherein the antibodies undergo in vivo recombination, junctional diversification, affinity maturation, and isotype class switching within the non-human vertebrate host, thereby enabling selection of antigen-specific fully human antibodies without in vitro humanization of constant regions.",
    "title": "Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies",
    "abstract": "The present invention relates to humanisation of antibodies in vivo. The invention provides non-human vertebrates, cells, populations and methods useful for humanising chimaeric antibodies in vivo. Using the present invention it is possible straightforwardly and rapidly to obtain antigen-specific antibodies that are fully human (ie, comprising human variable and constant regions) and have undergone recombination, junctional diversification, affinity maturation and isotype switching in vivo in a non-human vertebrate system. Furthermore, such antibodies are humanised (eg, totally human)—and selected—totally in vivo, and as such the present invention harnesses in vivo filtering for expressibility, affinity and biophysical characteristics in the context of the desired human variable and constant region pairings. This is avoids problems of down-grading antibody characteristics when humanising the constant region of chimaeric antibodies in vitro.",
    "domain": "C12"
  },
  {
    "statement_id": "RN135",
    "patent_id": "8524731",
    "claim": "Opioid antagonists, including peripherally restricted opioid antagonists, inhibit or reduce endothelial cell proliferation and migration associated with angiogenesis.",
    "title": "Use of opioid antagonists to attenuate endothelial cell proliferation and migration",
    "abstract": "The invention provides methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.",
    "domain": "C12"
  },
  {
    "statement_id": "RN136",
    "patent_id": "10597709",
    "claim": "A method for simultaneously amplifying multiple nucleic acid target loci in a single reaction volume using a library of primers designed to minimize formation of primer dimers and non-target amplicons, wherein primer selection criteria are applied across the entire primer library to ensure compatible co-amplification of all target regions.",
    "title": "Methods for simultaneous amplification of target loci",
    "abstract": "The invention provides methods for simultaneously amplifying multiple nucleic acid regions of interest in one reaction volume as well as methods for selecting a library of primers for use in such amplification methods. The invention also provides library of primers with desirable characteristics, such as minimal formation of amplified primer dimers or other non-target amplicons.",
    "domain": "C12"
  },
  {
    "statement_id": "RN137",
    "patent_id": "11458337",
    "claim": "A dual-mode ultrasound system that uses real-time image data to iteratively solve an optimization problem for selecting excitation waveforms for a transducer array, wherein user-selected control points within the imaging field of view define focusing gain targets, and the optimized waveforms are cascaded through virtual sub-arrays to adaptively refocus ultrasound energy for therapy delivery.",
    "title": "Adaptive refocusing of ultrasound transducer arrays using image data",
    "abstract": "A dual-mode ultrasound system provides real-time imaging and therapy delivery using a transducer array. The system may use various imaging modes to provide image data that may be used to select control points within an imaging field of view. The control points along with the image data may be used to solve an optimization problem to achieve desired focusing gains at one or more of the control points. The optimized solution may be used to produce excitation waveforms to generate new image data. The focusing gains may be evaluated and the optimization problem may be iterated until desired focusing gains are achieved. Virtual arrays may be defined and cascaded to provide flexibility in solving the optimization problem.",
    "domain": "C12"
  },
  {
    "statement_id": "RN138",
    "patent_id": "10227625",
    "claim": "A method for modifying endogenous genes in eukaryotic cells using large DNA targeting vectors (LTVECs) derived from cloned genomic DNA fragments larger than those used in conventional homologous recombination approaches, combined with a quantitative detection method to identify cells in which the LTVEC has correctly targeted the desired chromosomal locus via homologous recombination.",
    "title": "Methods of modifying eukaryotic cells",
    "abstract": "A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.",
    "domain": "C12"
  },
  {
    "statement_id": "RN139",
    "patent_id": "10655180",
    "claim": "A method for simultaneously amplifying multiple nucleic acid target loci in a single reaction volume using a library of primers specifically selected to minimize formation of primer dimers and non-target amplicons, wherein the primer library selection process evaluates inter-primer interactions across all primer pairs to achieve high-specificity multiplex amplification.",
    "title": "Methods for simultaneous amplification of target loci",
    "abstract": "The invention provides methods for simultaneously amplifying multiple nucleic acid regions of interest in one reaction volume as well as methods for selecting a library of primers for use in such amplification methods. The invention also provides library of primers with desirable characteristics, such as minimal formation of amplified primer dimers or other non-target amplicons.",
    "domain": "C12"
  },
  {
    "statement_id": "RN140",
    "patent_id": "10266804",
    "claim": "A method of co-culturing mammalian skeletal muscle cells and spinal motoneurons on carriers coated with a covalently bonded monolayer of trimethoxysilylpropyl diethylenetriamine (DETA) in a serum-free medium system, where muscle cells are plated first followed by motoneurons, and the co-culture is maintained in a mixture of two defined serum-free medium compositions.",
    "title": "Method of co-culturing mammalian muscle cells and motoneurons",
    "abstract": "The invention provides a method of co-culturing mammalian muscle cells and mammalian motoneurons. The method comprises preparing one or more carriers coated with a covalently bonded monolayer of trimethoxysilylpropyl diethylenetriamine (DETA); suspending isolated fetal mammalian skeletal muscle cells in serum-free medium according to medium composition 1; suspending isolated fetal mammalian spinal motoneurons in serum-free medium according to medium composition 1; plating the suspended muscle cells onto the one or more carriers at a predetermined density and allowing the muscle cells to attach; plating the suspended motoneurons at a predetermined density onto the one or more carriers and allowing the motoneurons to attach; covering the one or more carriers with a mixture of medium composition 1 and medium composition 2; and incubating the carriers covered in the media mixture.",
    "domain": "C12"
  },
  {
    "statement_id": "RN141",
    "patent_id": "10731151",
    "claim": "A method for synthesizing templated molecules in which a scaffold functional entity and a building block functional entity are each equipped with complementary dimerization domains that bring the two functional entities into close proximity upon interaction, thereby directing covalent bond formation between them while the synthesized molecule remains attached to the template that directed its synthesis.",
    "title": "Method for synthesising templated molecules",
    "abstract": "The invention relates to a method for synthesising templated molecules attached to the templated which directed the synthesis thereof. The method involves a template, a scaffold functional entity and a functional entity attached to a building block, which, in turn, is attached the template. The scaffold functional entity and the functional entity of the building block are both provided with complementary dimerization domains allowing the functional entities to come into close proximity when the complementary domains interact with to each other. The method may be used for generating libraries of templated molecules which may be selected for biological activity.",
    "domain": "C07"
  },
  {
    "statement_id": "RN142",
    "patent_id": "9284600",
    "claim": "A method for synthesizing a bifunctional complex comprising a display molecule part and a coding part, wherein a nascent bifunctional complex having both a chemical reaction site and a priming site is simultaneously reacted at the chemical reaction site with one or more chemical reactants while enzymatically adding nucleotide or oligonucleotide tags to the priming site that encode the identity of the reacted reactant(s).",
    "title": "Method for the synthesis of a bifunctional complex",
    "abstract": "Disclosed is a method for obtaining a bifunctional complex comprising a display molecule part and a coding part, wherein a nascent bifunctional complex comprising a chemical reaction site and a priming site for enzymatic addition of a tag is reacted at the chemical reaction site with one or more reactants, and provided with respective tag(s) identifying the reactant(s) at the priming site is using one or more enzymes.",
    "domain": "C07"
  },
  {
    "statement_id": "RN143",
    "patent_id": "11187702",
    "claim": "A method for quantifying enzyme molecules by distributing them into a plurality of discrete fluid partitions such that a subset of partitions each contain individual enzyme molecules, performing an enzyme-catalyzed reaction within those partitions, detecting the number of reaction-positive partitions, and determining the absolute amount of enzyme based on the counted partition number using digital quantification principles.",
    "title": "Enzyme quantification",
    "abstract": "The invention generally relates to methods for quantifying an amount of enzyme molecules. Systems and methods of the invention are provided for measuring an amount of target by forming a plurality of fluid partitions, a subset of which include the target, performing an enzyme-catalyzed reaction in the subset, and detecting the number of partitions in the subset. The amount of target can be determined based on the detected number.",
    "domain": "C07"
  },
  {
    "statement_id": "RN144",
    "patent_id": "10472623",
    "claim": "An antigen-binding molecule engineered to exhibit weaker antigen-binding activity at early endosomal pH (approximately pH 5.5-6.0) compared to plasma pH (approximately pH 7.4), enabling a single antibody molecule to repeatedly bind and release multiple antigen molecules in vivo, thereby extending plasma half-life and prolonging the duration of antigen-binding capacity.",
    "title": "Antigen-binding molecule capable of binding two or more antigen molecules repeatedly",
    "abstract": "The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen.",
    "domain": "C07"
  },
  {
    "statement_id": "RN145",
    "patent_id": "8979534",
    "claim": "An acellular mammalian tooth-shaped scaffold incorporating at least one bioactive compound that is chemotactic, osteogenic, dentinogenic, amelogenic, or cementogenic, configured for implantation into a tooth socket to recruit endogenous cells and regenerate tooth structures without pre-seeding with exogenous cells.",
    "title": "Tooth scaffolds",
    "abstract": "Provided is an acellular mammalian tooth-shaped scaffold including a compound that is chemotactic, osteogenic, dentinogenic, amelogenic, or cementogenic. Also provided is a method of replacing a tooth in the mouth of a mammal, where the tooth is absent and a tooth socket is present in the mouth at the position of the absent tooth. The method includes implanting an acellular scaffold having the shape of the missing tooth into the tooth socket. Additionally, a method of making a tooth scaffold is provided. The method includes synthesizing an acellular scaffold in the shape of a mammalian tooth and adding at least one compound that is chemotactic, osteogenic, dentinogenic, amelogenic, or cementogenic.",
    "domain": "C07"
  },
  {
    "statement_id": "RN146",
    "patent_id": "9186403",
    "claim": "A combination therapy composition comprising triciribine (an AKT inhibitor) and trastuzumab (a HER2-targeting monoclonal antibody) that exhibits reduced toxicity compared to monotherapy while treating tumors and cancers associated with abnormal cell proliferation.",
    "title": "Compositions including triciribine and trastuzumab and methods of use thereof",
    "abstract": "This application relates to combination therapies including triciribine and related compounds and trastuzumab or a salt thereof and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.",
    "domain": "C07"
  },
  {
    "statement_id": "RN147",
    "patent_id": "8255033",
    "claim": "An implantable device membrane system comprising a polymer formed from a high oxygen soluble material disposed adjacent to an oxygen-utilizing source, configured to dynamically retain high oxygen availability to the oxygen-utilizing source during oxygen deficits in the surrounding biological environment, enabling improved performance of enzyme-based electrochemical sensors or cell transplantation devices under low oxygen conditions.",
    "title": "Oxygen enhancing membrane systems for implantable devices",
    "abstract": "The present invention relates generally to systems and methods for increasing oxygen availability to implantable devices. The preferred embodiments provide a membrane system configured to provide protection of the device from the biological environment and/or a catalyst for enabling an enzymatic reaction, wherein the membrane system includes a polymer formed from a high oxygen soluble material. The high oxygen soluble polymer material is disposed adjacent to an oxygen-utilizing source on the implantable device so as to dynamically retain high oxygen availability to the oxygen-utilizing source during oxygen deficits. Membrane systems of the preferred embodiments are useful for implantable devices with oxygen-utilizing sources and/or that function in low oxygen environments, such as enzyme-based electrochemical sensors and cell transplantation devices.",
    "domain": "C07"
  },
  {
    "statement_id": "RN148",
    "patent_id": "8048672",
    "claim": "T-bet, a transcription factor encoded by an isolated nucleic acid molecule, regulates T helper cell differentiation, and compositions including T-bet polypeptides, antisense nucleic acids, recombinant expression vectors, and anti-T-bet antibodies can be used to modulate T-bet expression and/or activity in cells and to identify agents that alter Th1/Th2 immune responses.",
    "title": "T-bet compositions and methods of use thereof",
    "abstract": "Isolated nucleic acid molecules encoding T-bet, and isolated T-bet polypeptides, are provided. The invention further provides antisense nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals carrying a T-bet transgene. The invention further provides T-bet fusion proteins and anti-T-bet antibodies. Methods of using the T-bet compositions of the invention are also disclosed, including methods for detecting T-bet expression and/or activity in a biological sample, methods of modulating T-bet expression and/or activity in a cell, and methods for identifying agents that modulate the expression and/or activity of T-bet.",
    "domain": "C07"
  },
  {
    "statement_id": "RN149",
    "patent_id": "8461169",
    "claim": "Small molecule compounds that modulate the activity of both receptor protein tyrosine kinases c-kit and c-fms, useful for treating diseases mediated by one or both of these kinase receptors.",
    "title": "Compounds modulating c-fms and/or c-kit activity",
    "abstract": "Compounds active on the receptor protein tyrosine kinases c-kit and/or c-fms are provided herewith. Also provided herewith are compositions useful for treatment of c-kit mediated diseases or conditions and/or c-fms-mediated diseases or conditions, and methods for the use thereof.",
    "domain": "C07"
  },
  {
    "statement_id": "RN150",
    "patent_id": "9265784",
    "claim": "A combination therapy using a 4-anilino-3-cyanoquinoline compound (such as HKI-272, SKI-606, or EKB-569) together with capecitabine for the treatment of neoplasms including metastatic breast cancer and lung cancer, wherein the two agents are co-administered as an antineoplastic regimen optionally combined with additional anti-neoplastic or immunomodulatory agents.",
    "title": "Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine",
    "abstract": "A combination of a 4-anilino-3-cyanoquinoline compound (e.g. HKI-272, SKI-606, EKB-569) and a capecitabine compound in the treatment of a neoplasm is provided. Regimens, kits, and methods for treatment of neoplasm, including breast cancer including metastatic breast cancer, and lung cancer, using this combination, optionally in combination with other anti-neoplastic agents, or immune modulators are also described.",
    "domain": "C07"
  },
  {
    "statement_id": "RN151",
    "patent_id": "6720140",
    "claim": "Recombinational cloning using engineered recombination sites that direct site-specific recombination proteins to exchange DNA segments between molecules, enabling directional and sequence-specific transfer of DNA inserts into destination vectors in vitro and in vivo to produce chimeric DNA molecules with defined characteristics.",
    "title": "Recombinational cloning using engineered recombination sites",
    "abstract": "Recombinational cloning is provided by the use of nucleic acids, vectors and methods, in vitro and in vivo, for moving or exchanging segments of DNA molecules using engineered recombination sites and recombination proteins to provide chimeric DNA molecules that have the desired characteristic(s) and/or DNA segment(s).",
    "domain": "C07"
  },
  {
    "statement_id": "RN152",
    "patent_id": "8338618",
    "claim": "Novel derivatives of oleanolic acid, a pentacyclic triterpenoid, that function as dual antioxidant and anti-inflammatory modulators for treating cancer, neurological disorders, and oxidative stress-related pathologies through chemical modifications to the oleanolic acid scaffold.",
    "title": "Antioxidant inflammation modulators: novel derivatives of oleanolic acid",
    "abstract": "Disclosed herein are novel oleanolic acid derivatives. Methods of preparing these compounds are also disclosed. The oleanolic acid derivatives of this invention may be used for the treatment and prevention of many diseases, including cancer, neurological disorders, inflammation, and pathologies involving oxidative stress.",
    "domain": "C07"
  },
  {
    "statement_id": "RN153",
    "patent_id": "8222392",
    "claim": "A kit for detecting human telomerase reverse transcriptase (hTRT) nucleic acids comprising oligonucleotide probes or primers specifically designed to hybridize to hTRT polynucleotide sequences encoding the catalytic protein subunit of human telomerase, enabling diagnostic detection of telomerase activity in biological samples for cancer diagnosis and prognosis.",
    "title": "Kit for detection of telomerase reverse transcriptase nucleic acids",
    "abstract": "The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.",
    "domain": "C07"
  },
  {
    "statement_id": "RN154",
    "patent_id": "9449802",
    "claim": "A mass spectrometry method for characterizing large analytes such as biomolecules that applies a digital thresholding process to selectively filter singly- or multiply-charged ions based on signal intensity, enabling molecular mass analysis by discriminating target ions from background noise or interfering species.",
    "title": "Mass spectrometry with selective ion filtration by digital thresholding",
    "abstract": "The methods described herein generally relate to characterization of large analytes, such as biomolecules, by molecular mass analysis. Specifically, the methods are directed to molecular mass analysis of singly- or multiply-charged ions by selective ion filtering carried out by a digital thresholding process.",
    "domain": "C07"
  },
  {
    "statement_id": "RN155",
    "patent_id": "6979538",
    "claim": "A directed evolution method for obtaining novel binding proteins wherein DNA molecules encoding a family of similar potential binding domains fused to a bacterial or phage surface display signal are introduced into a genetic package (bacterial cell, spore, or phage), the displayed binding domains are screened against a target molecule, successful binders are isolated and used as templates to design a new family of potential binding domains, and the iterative selection-redesign cycle is repeated until a binding domain with desired affinity is obtained, exemplified using bovine pancreatic trypsin inhibitor variants displayed on M13 phage via the gene III protein transport signal.",
    "title": "Directed evolution of novel binding proteins",
    "abstract": "In order to obtain a novel binding protein against a chosen target, DNA molecules, each encoding a protein comprising one of a family of similar potential binding domains and a structural signal calling for the display of the protein on the outer surface of a chosen bacterial cell, bacterial spore or phage (genetic package) are introduced into a genetic package. The protein is expressed and the potential binding domain is displayed on the outer surface of the package. The cells or viruses bearing the binding domains which recognize the target molecule are isolated and amplified. The successful binding domains are then characterized. One or more of these successful binding domains is used as a model for the design of a new family of potential binding domains, and the process is repeated until a novel binding domain having a desired affinity for the target molecule is obtained. In one embodiment, the first family of potential binding domains is related to bovine pancreatic trypsin inhibitor, the genetic package is M13 phage, and the protein includes the outer surface transport signal of the M13 gene III protein.",
    "domain": "C07"
  },
  {
    "statement_id": "RN156",
    "patent_id": "9970005",
    "claim": "Double-stranded short interfering nucleic acid (siNA) molecules capable of mediating RNA interference (RNAi) to inhibit target gene expression, wherein the siNA molecules comprise chemically modified nucleotides that enhance stability and efficacy compared to unmodified RNA duplexes.",
    "title": "RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)",
    "abstract": "The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.",
    "domain": "C07"
  },
  {
    "statement_id": "RN157",
    "patent_id": "10196640",
    "claim": "An oligonucleotide composition comprising at least 2 different oligonucleotides each targeted to distinct regions of the same target gene, wherein the combination of oligonucleotides provides enhanced inhibition of protein synthesis in a cell compared to individual oligonucleotides used alone.",
    "title": "Oligonucleotide compositions with enhanced efficiency",
    "abstract": "The oligonucleotide compositions of the present invention make use of combinations of oligonucleotides. In one aspect, the invention features an oligonucleotide composition including at least 2 different oligonucleotides targeted to a target gene. This invention also provides methods of inhibiting protein synthesis in a cell and methods of identifying oligonucleotide compositions that inhibit synthesis of a protein in a cell.",
    "domain": "C07"
  },
  {
    "statement_id": "RN158",
    "patent_id": "10597660",
    "claim": "Adeno-associated viral (AAV) vectors encoding small interfering RNA (siRNA) molecules targeting the SOD1 gene are used to silence SOD1 expression as a therapeutic approach for treating amyotrophic lateral sclerosis (ALS).",
    "title": "Compositions and methods of treating amyotrophic lateral sclerosis (ALS)",
    "abstract": "The present invention relates to small interfering RNA (siRNA) molecules against the SOD1 gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating amyotrophic lateral sclerosis (ALS) using the siRNA molecules and AAV vectors.",
    "domain": "C07"
  },
  {
    "statement_id": "RN159",
    "patent_id": "9770467",
    "claim": "A cancer immunotherapy composition combining cyclic-di-nucleotide (CDN) STING agonists with allogeneic human tumor cell lines engineered to secrete GM-CSF, wherein the CDN activates dendritic cells via the STING cytoplasmic receptor while the GM-CSF-secreting tumor cells provide tumor-associated antigens and promote dendritic cell recruitment and proliferation.",
    "title": "Compositions and methods for cancer immunotherapy",
    "abstract": "The present invention provides a combination therapy which relies on a small molecule immune stimulator—cyclic-di-nucleotide (CDN)—that activates DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes) formulated with allogeneic human tumor cell lines engineered to secrete high amounts of GM-CSF. This combination therapy can provide an ideal synergy of multiple tumor associated antigens, DC recruitment and proliferation, coupled with a potent DC activation stimulus.",
    "domain": "C07"
  },
  {
    "statement_id": "RN160",
    "patent_id": "10138435",
    "claim": "A method of manufacturing ASTM-compliant renewable diesel and jet fuel by fermenting genetically engineered oil-bearing microbes on carbohydrate feedstocks including cane bagasse, sugar beet pulp, or corn stover to produce triglyceride oils, followed by hydrotreating, hydrocracking, and isomerization of the microbially-derived triglyceride oils to convert them into alkane-based fuels.",
    "title": "Renewable diesel and jet fuel from microbial sources",
    "abstract": "The invention provides methods of manufacturing alkanes from triglyceride oils produced through fermentation of oil-bearing microbes. The processes provided herein can utilize a variety of carbohydrate feedstocks including cane bagasse, sugar beet pulp, corn stover, glycerol, corn starch, sorghum, molasses, waste glycerol, and other renewable materials. These processes further comprise hydrotreating, hydrocracking, isomerization, distillation, and other petrochemical processes for use with oil-bearing microbes and products derived therefrom to manufacture fuels. Particular embodiments include the manufacture of ASTM D975 and ASTM D1655 compliant fuels. Genetically engineered microbes provided herein can be used in the manufacture of renewable diesel and renewable jet fuel.",
    "domain": "C07"
  },
  {
    "statement_id": "RN161",
    "patent_id": "7893075",
    "claim": "Small molecule compounds that dually modulate the activity of both c-kit and c-fms receptor protein tyrosine kinases, useful for treating diseases mediated by one or both of these kinase receptors.",
    "title": "Compounds modulating c-fms and/or c-kit activity and uses therefor",
    "abstract": "Compounds active on the receptor protein tyrosine kinases c-kit and/or c-fms are provided herewith. Also provided herewith are compositions useful for treatment of c-kit mediated diseases or conditions and/or c-fms-mediated diseases or conditions, and methods for the use thereof.",
    "domain": "C07"
  },
  {
    "statement_id": "RN162",
    "patent_id": "11542506",
    "claim": "Adeno-associated viral (AAV) vectors encoding small interfering RNA (siRNA) molecules targeting the SOD1 gene are used to deliver and express SOD1-silencing siRNA for the treatment of amyotrophic lateral sclerosis (ALS).",
    "title": "Compositions and methods of treating amyotrophic lateral sclerosis (ALS)",
    "abstract": "The present invention relates to small interfering RNA (siRNA) molecules against the SOD1 gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating amyotrophic lateral sclerosis (ALS) using the siRNA molecules and AAV vectors.",
    "domain": "C07"
  },
  {
    "statement_id": "RN163",
    "patent_id": "7708996",
    "claim": "Isolated antibodies and binding fragments thereof that specifically bind to DR3 (Death Domain Containing Receptor 3) or DR3-V1 polypeptides, which are members of the tumor necrosis factor receptor family containing a death domain, wherein said antibodies can be used to identify agonists or antagonists of DR3 and DR3-V1 signaling activity.",
    "title": "DR3 antibodies",
    "abstract": "The present invention relates to novel Death Domain Containing Receptor (DR3 and DR3-V1) proteins that are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR3 and DR3-V1 proteins. DR3 and DR3-V1 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are antibodies and fragments thereof that bind to polypeptides of the invention. The invention further relates to screening methods for identifying agonists and antagonists of DR3 and DR3-V1 activity.",
    "domain": "C07"
  },
  {
    "statement_id": "RN164",
    "patent_id": "11186853",
    "claim": "Non-naturally occurring microbial organisms engineered with a fatty alcohol, fatty aldehyde, or fatty acid biosynthetic pathway combined with select gene disruptions or enzyme attenuations that enable selective production of fatty alcohols, fatty aldehydes, or fatty acids of a specified carbon chain length, optionally coupled with an acetyl-CoA pathway to increase precursor availability and product yield.",
    "title": "Microorganisms and methods for production of specific length fatty alcohols and related compounds",
    "abstract": "The invention provides non-naturally occurring microbial organisms containing a fatty alcohol, fatty aldehyde or fatty acid pathway, wherein the microbial organisms selectively produce a fatty alcohol, fatty aldehyde or fatty acid of a specified length. Also provided are non-naturally occurring microbial organisms having a fatty alcohol, fatty aldehyde or fatty acid pathway, wherein the microbial organisms further include an acetyl-CoA pathway. In some aspects, the microbial organisms of the invention have select gene disruptions or enzyme attenuations that increase production of fatty alcohols, fatty aldehydes or fatty acids. The invention additionally provides methods of using the above microbial organisms to produce a fatty alcohol, a fatty aldehyde or a fatty acid.",
    "domain": "C07"
  },
  {
    "statement_id": "RN165",
    "patent_id": "6506906",
    "claim": "Synthetic polyamides containing N-methylpyrrole and N-methylimidazole amino acids that bind the minor groove of B-form double helical DNA with subnanomolar affinity to any predetermined DNA sequence, governed by a defined pairing code in which imidazole/pyrrole heterocyclic pairs distinguish G·C from C·G and A·T base pairs, enabling rational design of molecules that recognize specific DNA sequences with affinities and specificities comparable to transcription factors.",
    "title": "Preparation and use of bifunctional molecules having DNA sequence binding specificity",
    "abstract": "Small molecule polyamides that specifically bind with subnanomolar affinity to any predetermined sequence in the human genome with potential use in molecular biology and human medicine are described. Further, the designed compounds which target the minor groove of B-form double helical DNA offer a general approach for the control of gene-expression. Simple rules are disclosed which provide for rational control of the DNA-binding sequence specificity of synthetic polyamides containing N-methylpyrrole and N-methylimidazole amino acids. A series of molecular templates for polyamide design are disclosed which provide for small molecules which recognize predetermined DNA sequences with affinities and specificities comparable to sequence-specific DNA-binding proteins such as transcription factors. These design rule are applied to provide a polyamide for specific targeting of a predetermined 7 base pair sequence from a conserved HIV gene promoter at subnanomolar concentration. The pyrrole-imidazole polyamides described herein represent the only class of designed small molecules to date that can bind any predetermined sequence of double helical DNA.",
    "domain": "C07"
  },
  {
    "statement_id": "RN166",
    "patent_id": "10758542",
    "claim": "Substituted pyrazolo[1,5-a]pyrimidine compounds that selectively inhibit Trk (tropomyosin receptor kinase) kinases, useful for treating pain, cancer, inflammation, neurodegenerative diseases, and infectious diseases mediated by Trk kinase activity.",
    "title": "Substituted pyrazolo[l,5-a]pyrimidine compounds as Trk kinase inhibitors",
    "abstract": "Compounds of Formula I: and salts thereof in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.",
    "domain": "C07"
  },
  {
    "statement_id": "RN167",
    "patent_id": "7745581",
    "claim": "T-bet is a T-box transcription factor whose isolated nucleic acid sequence and protein are provided, enabling recombinant expression vectors, transgenic animal models, fusion proteins, and anti-T-bet antibodies for modulating T-bet transcriptional activity in immune cells and identifying agents that alter T-bet function.",
    "title": "T-bet compositions and methods of use thereof",
    "abstract": "Isolated nucleic acid molecules encoding T-bet, and isolated T-bet proteins, are provided. The invention further provides antisense nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals carrying a T-bet transgene. The invention further provides T-bet fusion proteins and anti-T-bet antibodies. Methods of using the T-bet compositions of the invention are also disclosed, including methods for detecting T-bet activity in a biological sample, methods of modulating T-bet activity in a cell, and methods for identifying agents that modulate the activity of T-bet.",
    "domain": "C07"
  },
  {
    "statement_id": "RN168",
    "patent_id": "11459611",
    "claim": "A sequencing method that assigns a unique identifier (UID) to each individual DNA template molecule prior to PCR amplification, then groups sequencing reads sharing the same UID into families and calls a true variant only when ≥95% of reads within a UID-family contain the identical mutation, thereby distinguishing true rare mutations from PCR and sequencing errors in massively parallel sequencing.",
    "title": "Safe sequencing system",
    "abstract": "The identification of mutations that are present in a small fraction of DNA templates is essential for progress in several areas of biomedical research. Though massively parallel sequencing instruments are in principle well-suited to this task, the error rates in such instruments are generally too high to allow confident identification of rare variants. We here describe an approach that can substantially increase the sensitivity of massively parallel sequencing instruments for this purpose. One example of this approach, called “Safe-SeqS” for (Safe-Sequencing System) includes (i) assignment of a unique identifier (UID) to each template molecule; (ii) amplification of each uniquely tagged template molecule to create UID-families; and (iii) redundant sequencing of the amplification products. PCR fragments with the same UID are truly mutant (“super-mutants”) if ≥95% of them contain the identical mutation. We illustrate the utility of this approach for determining the fidelity of a polymerase, the accuracy of oligonucleotides synthesized in vitro, and the prevalence of mutations in the nuclear and mitochondrial genomes of normal cells.",
    "domain": "C07"
  },
  {
    "statement_id": "RN169",
    "patent_id": "11453913",
    "claim": "A sequencing method that assigns a unique identifier (UID) to each individual DNA template molecule, amplifies each uniquely tagged molecule to create UID-families, and then performs redundant sequencing of the amplification products, wherein PCR fragments sharing the same UID are classified as true mutations only when ≥95% of the family members contain the identical sequence variant, thereby enabling confident detection of rare mutations present in a small fraction of DNA templates using massively parallel sequencing instruments.",
    "title": "Safe sequencing system",
    "abstract": "The identification of mutations that are present in a small fraction of DNA templates is essential for progress in several areas of biomedical research. Though massively parallel sequencing instruments are in principle well-suited to this task, the error rates in such instruments are generally too high to allow confident identification of rare variants. We here describe an approach that can substantially increase the sensitivity of massively parallel sequencing instruments for this purpose. One example of this approach, called “Safe-SeqS” for (Safe-Sequencing System) includes (i) assignment of a unique identifier (UID) to each template molecule; (ii) amplification of each uniquely tagged template molecule to create UID-families; and (iii) redundant sequencing of the amplification products. PCR fragments with the same UID are truly mutant (“super-mutants”) if ≥95% of them contain the identical mutation. We illustrate the utility of this approach for determining the fidelity of a polymerase, the accuracy of oligonucleotides synthesized in vitro, and the prevalence of mutations in the nuclear and mitochondrial genomes of normal cells.",
    "domain": "C07"
  },
  {
    "statement_id": "RN170",
    "patent_id": "9187548",
    "claim": "Antibodies or antigen-binding fragments thereof that immunospecifically bind to B Lymphocyte Stimulator (BLyS) protein, wherein said antibodies neutralize aberrant BLyS expression or function and are used to prevent, treat, or ameliorate diseases or disorders associated with dysregulated BLyS activity.",
    "title": "Antibodies that immunospecifically bind to B lymphocyte stimulator protein",
    "abstract": "The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate B Lymphocyte Stimulator function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator.",
    "domain": "C07"
  },
  {
    "statement_id": "RN171",
    "patent_id": "11168344",
    "claim": "A method for regulating polypeptide association to promote heterodimer formation by modifying amino acid residues at the polypeptide interface to carry the same type of charge, thereby electrostatically disfavoring homodimer formation and favoring heterodimer formation for producing bispecific antibodies.",
    "title": "Methods for producing polypeptides by regulating polypeptide association",
    "abstract": "In the course of the present invention, it was discovered that one could regulate association between polypeptides by modifying amino acid residues that form the interface during the association to amino acids carrying the same type of charge. In this context, the present invention enables efficient formation of heterologous molecules. For example, the present invention can be suitably applied to the preparation of bispecific antibodies.",
    "domain": "C07"
  },
  {
    "statement_id": "RN172",
    "patent_id": "10153513",
    "claim": "A triblock brush copolymer having an ABC or ABA block configuration where each block bears polymer side chains (brush architecture) that provide steric properties enabling rapid self-assembly into morphologies distinct from those of conventional non-brush block copolymers, while imparting tunable mechanical, elastic, ionic, or electronic properties through selection of the side chain polymer groups.",
    "title": "Triblock brush block copolymers",
    "abstract": "Provided herein is a class of copolymers, including triblock brush copolymers having specific block configurations, for example, ABC triblock brush copolymers and ABA triblock brush copolymers. In an embodiment, for example, copolymers of the invention incorporate various polymer side chain groups which contribute beneficial physical, chemical, or electronic properties such as increased mechanical or elastic strength, improved ionic or electric conductivity. In some embodiments, the provided copolymers exhibit advantageous steric properties allowing for rapid self-assembly into a variety of morphologies that are substantially different than non-brush, block copolymers.",
    "domain": "C07"
  },
  {
    "statement_id": "RN173",
    "patent_id": "8101181",
    "claim": "Antibodies or antigen-binding fragments thereof that immunospecifically bind to B Lymphocyte Stimulator (BLyS) protein, wherein said antibodies are used to prevent, treat, or ameliorate diseases associated with aberrant BLyS expression or inappropriate BLyS function by administering an effective amount of the antibody to an animal.",
    "title": "Antibodies that immunospecifically bind to B lymphocyte stimulator protein",
    "abstract": "The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate B Lymphocyte Stimulator function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator.",
    "domain": "C07"
  },
  {
    "statement_id": "RN174",
    "patent_id": "8557780",
    "claim": "Monomethylauristatin E (MMAE) and monomethylauristatin F (MMAF) peptide compounds are conjugated to targeting ligands via a maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (mc-val-cit-PAB) linker to form ligand-drug conjugates that retain cytotoxic activity both in vitro and in vivo.",
    "title": "Monomethylvaline compounds capable of conjugation to ligands",
    "abstract": "Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.",
    "domain": "A61"
  },
  {
    "statement_id": "RN175",
    "patent_id": "10709701",
    "claim": "An antibody-drug conjugate (IMMU-140) comprising SN-38 attached via a CL2A linker to the anti-HLA-DR humanized antibody hL243, administered at dosages of 3-18 mg/kg, which reduces solid tumor size, eliminates metastases, and treats HLA-DR-positive hematologic cancers including AML, ALL, and multiple myeloma that are resistant to standard radiation, chemo-, or immunotherapy.",
    "title": "Efficacy of anti-HLA-DR antibody drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers",
    "abstract": "The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an anti-HLA-DR antibody or antigen-binding antibody fragment. The immunoconjugate may be administered at a dosage of between 3 mg/kg and 18 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg, more preferably 8, 10 or 12 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. The methods and compositions are particularly useful for treating AML, ALL or multiple myeloma.",
    "domain": "A61"
  },
  {
    "statement_id": "RN176",
    "patent_id": "8222373",
    "claim": "Humanized monoclonal antibodies and antigen-binding fragments thereof that specifically bind sphingosine-1-phosphate (S1P), wherein the antibodies comprise humanized framework regions grafted with complementarity-determining regions reactive to S1P, for use in treating diseases associated with aberrant S1P levels.",
    "title": "Humanized antibodies and compositions for binding sphingosine-1-phosphate",
    "abstract": "The present invention relates to anti-S1P agents, particularly humanized monoclonal antibodies (and antigen binding fragments thereof) specifically reactive with S1P, compositions containing such antibodies (or fragments), and the use of such antibodies (or fragments), for example, to treat diseases and conditions associated with aberrant levels of S1P.",
    "domain": "A61"
  },
  {
    "statement_id": "RN177",
    "patent_id": "8252739",
    "claim": "An albumin fusion protein comprising a therapeutic protein genetically fused to human serum albumin or a fragment thereof, wherein the fusion extends the half-life of the therapeutic protein in vivo while maintaining biological activity, encoded by a recombinant nucleic acid molecule expressible in a host cell.",
    "title": "Albumin fusion proteins",
    "abstract": "The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.",
    "domain": "A61"
  },
  {
    "statement_id": "RN178",
    "patent_id": "8828721",
    "claim": "A method of inducing myelination of isolated motoneurons in vitro by co-culturing isolated motoneurons deposited on a non-biological substrate with a covalently attached DETA monolayer together with isolated Schwann cells in a defined serum-free medium supplemented with L-ascorbic acid, until the motoneurons form Nodes of Ranvier indicative of myelination.",
    "title": "Method of myelinating isolated motoneurons",
    "abstract": "The present invention provides a method of inducing myelination of isolated motoneurons by preparing a non-biological substrate having thereon a covalently attached monolayer of DETA; depositing isolated motoneurons on the substrate in a defined serum-free medium; plating isolated Schwann cells cultured in the defined serum-free medium onto the motoneurons, thereby initiating a co-culture; and passaging the co-culture as necessary into fresh, defined serum-free medium supplemented with L-ascorbic acid at least until the motoneurons form Nodes of Ranvier indicative of myelination. The invention also includes a method of testing for new drugs effective in demyelinating diseases. Additionally, cellular products provided by the invention include an isolated motoneurons myelinated or remyelinated in vitro according to the methods disclosed.",
    "domain": "A61"
  },
  {
    "statement_id": "RN179",
    "patent_id": "10240120",
    "claim": "A method of culturing mixotrophic microorganisms wherein phototrophic and heterotrophic metabolic activities are balanced such that CO2 produced by heterotrophic respiration is consumed by phototrophic photosynthesis and O2 produced by photosynthesis is consumed by heterotrophic respiration, thereby minimizing or eliminating the need for externally supplied gases.",
    "title": "Balanced mixotrophy method",
    "abstract": "Methods of culturing mixotrophic microorganisms in a state of balanced gas composition are disclosed. Parameters of a culture of mixotrophic microorganisms may be controlled to reduce the requirements of externally supplied gases and optimize the production and consumption of gases within the culture by the phototrophic and heterotrophic metabolisms of the mixotrophic microorganisms.",
    "domain": "A61"
  },
  {
    "statement_id": "RN180",
    "patent_id": "10918705",
    "claim": "A chimeric antigen receptor (CAR) comprising an endodomain that incorporates both MyD88-derived and CD40-derived polypeptide sequences as costimulatory elements, wherein T cells expressing this CAR construct receive costimulatory signaling through the MyD88 and CD40 pathways upon antigen recognition to enhance immune activation against target antigens.",
    "title": "Costimulation of chimeric antigen receptors by MYD88 and CD40 polypeptides",
    "abstract": "The technology relates generally to the field of immunology and relates in part to methods for activating T cells and other cells resulting in an immune response against a target antigen. The technology also relates to costimulation of therapeutic cells that express chimeric antigen receptors that recognize target antigens using chimeric MyD88- and CD40-derived polypeptides. The technology further relates in part to therapeutic cells that express chimeric antigen receptors, wherein the chimeric antigen receptors have an endodomain that includes MyD88- and CD40-derived polypeptides, and methods for treating patients using the modified therapeutic cells.",
    "domain": "A61"
  },
  {
    "statement_id": "RN181",
    "patent_id": "8470532",
    "claim": "An aptamer-based colorimetric sensor system comprising oligonucleotide-functionalized particles assembled into an aggregate via a linker, wherein binding of a target analyte to the aptamer causes disaggregation of the particle assembly, producing a detectable colorimetric signal change that indicates the presence and concentration of the analyte.",
    "title": "Aptamer-based colorimetric sensor systems",
    "abstract": "The present invention provides an aptamer-based colorimetric sensor system for determining the presence and optionally the concentration of an analyte in a sample. Methods of utilizing the sensor system and kits that include the sensor also are provided. The sensor utilizes a linker and oligonucleotide functionalized particles to form an aggregate, which disaggregates in response to the analyte.",
    "domain": "A61"
  },
  {
    "statement_id": "RN182",
    "patent_id": "8449603",
    "claim": "An endoprosthesis such as a drug-eluting stent incorporating hollow elements integrated within a porous surface coating, where the hollow elements are structurally embedded in the coating to enable controlled drug elution from the stent surface.",
    "title": "Endoprosthesis coating",
    "abstract": "An endoprosthesis, e.g., a stent (e.g., a drug eluting stent), that includes a porous surface and hollow elements integrated with a coating on the surface and a method of making the same are disclosed.",
    "domain": "A61"
  },
  {
    "statement_id": "RN183",
    "patent_id": "10111954",
    "claim": "A combination therapy comprising a leukocyte redirecting bispecific antibody (specifically anti-CD3×anti-CD19) formed as a dock-and-lock (DNL) complex, co-administered with one or more of interferon-α, checkpoint inhibitor antibodies, or antibody-drug conjugates, wherein the bispecific antibody redirects effector T cells, NK cells, monocytes, or neutrophils to mediate cytotoxicity against cancer or infectious disease cells expressing the targeted disease antigen.",
    "title": "Combination therapy for inducing immune response to disease",
    "abstract": "The present invention concerns combinations of two or more agents for inducing an immune response to cancer or infectious disease. Agents may include leukocyte redirecting complexes, antibody-drug conjugates, interferons (preferably interferon-α), and/or checkpoint inhibitor antibodies. The leukocyte redirecting complexes have at least one binding site for a leukocyte antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a DNL™ complex. More preferably, the complex comprises a bispecific antibody (bsAb). Most preferably, the bsAb is an anti-CD3× anti-CD19 bispecific antibody, although antibodies against other leukocyte antigens and/or disease-associated antigens may be used. The complex is capable of targeting effector T cells, NK cells, monocytes or neutrophils to induce leukocyte-mediated cytotoxicity of cells associated with cancer or infectious disease. The cytotoxic immune response is enhanced by co-administration of interferon, checkpoint inhibitor antibody and/or ADC.",
    "domain": "A61"
  },
  {
    "statement_id": "RN184",
    "patent_id": "10669538",
    "claim": "A method for synthesizing templated molecules wherein the synthesized molecules remain covalently or non-covalently linked to the nucleic acid template that directed their synthesis, enabling the generation of screenable libraries in which each molecule is physically associated with the genetic information encoding its structure.",
    "title": "Templated molecules and methods for using such molecules",
    "abstract": "The present invention relates to a method for synthesising templated molecules. In one aspect of the invention, the templated molecules are linked to the template which templated the synthesis thereof. The invention allows the generation of libraries which can be screened for e.g. therapeutic activity.",
    "domain": "A61"
  },
  {
    "statement_id": "RN185",
    "patent_id": "7982879",
    "claim": "An angle-resolved Fourier-domain optical coherence tomography system that simultaneously detects signals from a plurality of backscattered electromagnetic radiations returned from a sample at multiple angles outside the illumination solid angle, wherein depth information at multiple sample depths is independently extractable from each individual angular channel without requiring combination with other angular channels.",
    "title": "Methods and systems for performing angle-resolved fourier-domain optical coherence tomography",
    "abstract": "Arrangements, apparatus and methods are provided according to exemplary embodiments of the present invention. In particular, at least one first electro-magnetic radiation may be received and at least one second electro-magnetic radiation within a solid angle may be forwarded to a sample. The second electro-magnetic radiation may be associated with the first electro-magnetic radiation. A plurality of third electro-magnetic radiations can be received from the sample which is associated with the second electro-magnetic radiation, and at least one portion of the third electro-magnetic radiation is provided outside a periphery of the solid angle. Signals associated with each of the third electro-magnetic radiations can be simultaneously detected, with the signals being associated with information for the sample at a plurality of depths thereof. The depths can be determined using at least one of the third electro-magnetic radiations without a need to utilize another one of the third electro-magnetic radiations.",
    "domain": "A61"
  },
  {
    "statement_id": "RN186",
    "patent_id": "8097926",
    "claim": "A medical device integrating stretchable or flexible circuitry with arrays of active sensing and therapeutic elements on a single substrate that conforms to curved biological tissue surfaces such as cardiac, neural, or luminal walls, enabling simultaneous conformal sensing and therapy delivery through direct tissue contact.",
    "title": "Systems, methods, and devices having stretchable integrated circuitry for sensing and delivering therapy",
    "abstract": "System, devices and methods are presented that integrate stretchable or flexible circuitry, including arrays of active devices for enhanced sensing, diagnostic, and therapeutic capabilities. The invention enables conformal sensing contact with tissues of interest, such as the inner wall of a lumen, a the brain, or the surface of the heart. Such direct, conformal contact increases accuracy of measurement and delivery of therapy. Further, the invention enables the incorporation of both sensing and therapeutic devices on the same substrate allowing for faster treatment of diseased tissue and fewer devices to perform the same procedure.",
    "domain": "A61"
  },
  {
    "statement_id": "RN187",
    "patent_id": "9975249",
    "claim": "A robotic limb controller that uses a neuromuscular model comprising a muscle model, muscle geometry, and reflex feedback loop to generate torque or impedance commands for joint control, where model parameters governing the relationship between sensory feedback and muscle activation are dynamically adjusted based on data from intrinsic and/or extrinsic sensors.",
    "title": "Neuromuscular model-based sensing and control paradigm for a robotic leg",
    "abstract": "A neuromuscular model-based controller for a robotic limb having at least one joint includes a neuromuscular model having a muscle model, muscle geometry and reflex feedback loop to determine at least one torque or impedance command to be sent to the robotic limb. One or more parameters that determine relation between feedback data and activation of the muscle model are adjusted consequent to sensory data from at least one of an intrinsic sensor and an extrinsic sensor. A controller in communication with the neuromuscular model is configured to receive the at least one torque or impedance command and controls at least one of position, torque and impedance of the robotic limb joint.",
    "domain": "A61"
  },
  {
    "statement_id": "RN188",
    "patent_id": "10464976",
    "claim": "A reproducible high-yield method for producing neuromodulatory oligomers of amyloid-β(1-42) protein, wherein the oligomers are used to generate oligomer-specific antibodies that selectively recognize amyloid-β(1-42) oligomeric forms as distinct from monomers and fibrils for diagnostic and therapeutic applications in Alzheimer's disease.",
    "title": "Amyloid β(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof",
    "abstract": "The invention relates to neuromodulatory oligomers of the amyloid-β(1-42) protein, a particular production method, by means of which the oligomer can be obtained in a reproducible manner at high yield, the use of the oligomers as diagnostic and therapeutics agents, for the generation of oligomer-specific antibodies and for the discovery of substances which can interact with the oligomers and in the formation thereof. Corresponding methods for the production of the antibodies and for discovery of the substances are also disclosed as are the antibodies themselves and the use of the antibodies or substances as diagnostic and therapeutic agents. The invention further relates to derivatives of the oligomers and oligomers based on abbreviated forms of the amyloid-β(1-42) proteins, the production and use thereof.",
    "domain": "A61"
  },
  {
    "statement_id": "RN189",
    "patent_id": "10793507",
    "claim": "A lipid composition comprising triacylglycerol in which docosapentaenoic acid (DPA) and/or docosahexaenoic acid (DHA) are preferentially esterified at the sn-2 position of the glycerol backbone, along with processes for producing such positionally-specific long-chain polyunsaturated fatty acid triacylglycerols.",
    "title": "Lipid compositions comprising triacylglycerol with long-chain polyunsaturated fatty acids at the SN-2 position",
    "abstract": "The present invention relates to lipid comprising docosapentaenoic acid and/or docosahexaenoic acid preferentially esterified at the sn-2 position of triacylglycerol, and processes for producing and using the lipid.",
    "domain": "A61"
  },
  {
    "statement_id": "RN190",
    "patent_id": "9221177",
    "claim": "A robotic limb controller that uses a neuromuscular model comprising a muscle model, muscle geometry, and reflex feedback loop to generate torque or impedance commands, where model parameters governing the relationship between sensory feedback and muscle activation are dynamically adjusted based on data from intrinsic and/or extrinsic sensors to control joint position, torque, and impedance.",
    "title": "Neuromuscular model-based sensing and control paradigm for a robotic leg",
    "abstract": "A neuromuscular model-based controller for a robotic limb having at least one joint includes a neuromuscular model having a muscle model, muscle geometry and reflex feedback loop to determine at least one torque or impedance command to be sent to the robotic limb. One or more parameters that determine relation between feedback data and activation of the muscle model are adjusted consequent to sensory data from at least one of an intrinsic sensor and an extrinsic sensor. A controller in communication with the neuromuscular model is configured to receive the at least one torque or impedance command and controls at least one of position, torque and impedance of the robotic limb joint.",
    "domain": "A61"
  },
  {
    "statement_id": "RN191",
    "patent_id": "9221896",
    "claim": "Albumin fusion proteins comprising a therapeutic protein genetically fused to human serum albumin or a fragment thereof, wherein the fusion extends the half-life of the therapeutic protein in vivo, encoded by recombinant nucleic acid molecules expressible in host cells.",
    "title": "Albumin fusion proteins",
    "abstract": "The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.",
    "domain": "A61"
  },
  {
    "statement_id": "RN192",
    "patent_id": "11377439",
    "claim": "Heterocyclic prolinamide derivatives that function as inhibitors of HTRA1 serine protease activity, wherein the compounds are designed to prevent or treat age-related macular degeneration (including dry-AMD, wet-AMD, and geographic atrophy), diabetic retinopathy, and related retinal degenerative diseases by inhibiting HTRA1-mediated pathological processes in the eye.",
    "title": "Heterocyclic prolinamide derivatives",
    "abstract": "This invention is directed to novel heterocyclic prolinamide derivatives of Formula (I), and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., (s) controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye. These diseases include dry-AMD, wet-AMD, geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells. The invention disclosed herein is further directed to methods of prevention, slowing the progress of, and treatment of dry-AMD, wet-AMD, and geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells, comprising: administration of a therapeutically effective amount of compound of the invention. The compounds of the invention are inhibitors of HTRA1. Thus, the compounds of the invention are useful in the prevention and treatment of a wide range of diseases mediated (in whole or in part) by HTRA1. The compounds of the invention are also useful for inhibiting HTRA1 protease activity in an eye or locus of an arthritis or related condition.",
    "domain": "A61"
  },
  {
    "statement_id": "RN193",
    "patent_id": "11279694",
    "claim": "Alvocidib prodrug compounds having a modified chemical structure where at least one of three defined substituent groups (R1, R2, R3) is not hydrogen, designed to be converted in vivo to the active CDK inhibitor alvocidib for treating diseases associated with overexpression of cyclin-dependent kinases.",
    "title": "Alvocidib prodrugs and their use as protein kinase inhibitors",
    "abstract": "Compounds having the following structure (I) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are as defined herein, and wherein at least one of R1, R2 and R3 is not H, are provided. Pharmaceutical compositions comprising the compounds and methods for use of the compounds for treating diseases associated with overexpression of a cyclin-dependent kinase (CDK) are also provided.",
    "domain": "A61"
  },
  {
    "statement_id": "RN194",
    "patent_id": "11512145",
    "claim": "A bifunctional fusion antibody comprising an anti-human insulin receptor antibody conjugated to α-L-Iduronidase enzyme, administered systemically to deliver therapeutic α-L-Iduronidase across the blood-brain barrier via insulin receptor-mediated transcytosis for treating CNS α-L-Iduronidase deficiency, with dosing based on quantified CNS uptake characteristics of the fusion construct.",
    "title": "Methods and compositions for increasing alpha-L-iduronidase activity in the CNS",
    "abstract": "Provided herein are methods and compositions for treating a subject suffering from a deficiency in α-L-Iduronidase in the CNS. The methods include systemic administration of a bifunctional fusion antibody comprising an antibody to a human insulin receptor and an α-L-Iduronidase. A therapeutically effective systemic dose is based on the specific CNS uptake characteristics of human insulin receptor antibody-α-L-Iduronidase fusion antibodies as described herein.",
    "domain": "A61"
  },
  {
    "statement_id": "RN195",
    "patent_id": "8934965",
    "claim": "A conformable brain-surface electrode array comprising a flexible substrate supporting an actively multiplexed electronic circuit and a barrier layer, wherein high-density electrodes provide electrical contact with brain tissue to enable simultaneous monitoring and actuation of spatio-temporal electrical waveforms at high spatial and temporal resolution over large cortical surface areas.",
    "title": "Conformable actively multiplexed high-density surface electrode array for brain interfacing",
    "abstract": "Provided are methods and devices for interfacing with brain tissue, specifically for monitoring and/or actuation of spatio-temporal electrical waveforms. The device is conformable having a high electrode density and high spatial and temporal resolution. A conformable substrate supports a conformable electronic circuit and a barrier layer. Electrodes are positioned to provide electrical contact with a brain tissue. A controller monitors or actuates the electrodes, thereby interfacing with the brain tissue. In an aspect, methods are provided to monitor or actuate spatio-temporal electrical waveform over large brain surface areas by any of the devices disclosed herein.",
    "domain": "A61"
  },
  {
    "statement_id": "RN196",
    "patent_id": "11116821",
    "claim": "A method for treating tracheobronchomalacia (TBM) in a patient diagnosed with hypophosphatasia (HPP) by administering a soluble alkaline phosphatase (sALP), thereby addressing the TBM as a clinical manifestation of the underlying HPP condition.",
    "title": "Methods for treating tracheobronchomalacia",
    "abstract": "The disclosure features methods for treating tracheobronchomalacia (TBM) in a patient having hypophosphatasia (HPP), such as an infant, by administering a soluble alkaline phosphatase (sALP) to the patient.",
    "domain": "A61"
  },
  {
    "statement_id": "RN197",
    "patent_id": "9359430",
    "claim": "Monoclonal antibodies 10F4 and 3C5 that selectively bind to Abeta globulomer conformers, distinguishing them from Abeta monomers and fibrils, for use in the treatment and diagnosis of Alzheimer's Disease.",
    "title": "Abeta conformer selective anti-Abeta globulomer monoclonal antibodies",
    "abstract": "The subject invention relates to monoclonal antibodies that may be used in the treatment and diagnosis of Alzheimer's Disease. In particular, the present invention relates to monoclonal antibodies referred to as 10F4 and 3C5 and to other monoclonal antibodies (e.g., murine, human or humanized) having similar properties thereto.",
    "domain": "A61"
  },
  {
    "statement_id": "RN198",
    "patent_id": "8886273",
    "claim": "A continuous glucose measurement system configured for direct insertion into a host's vascular system, comprising a vascular access device integrated with an analyte sensor and sensor electronics to enable continuous real-time glucose monitoring within the circulatory system.",
    "title": "Analyte sensor",
    "abstract": "Systems and methods of use for continuous analyte measurement of a host's vascular system are provided. In some embodiments, a continuous glucose measurement system includes a vascular access device, a sensor and sensor electronics, the system being configured for insertion into communication with a host's circulatory system.",
    "domain": "A61"
  },
  {
    "statement_id": "RN199",
    "patent_id": "8557788",
    "claim": "Blocking the interaction between thrombospondin-1 (TSP1) and CD47 in blood vessels causes vasodilation and increases blood flow and tissue perfusion, thereby preventing tissue ischemia and damage under conditions of reduced blood flow caused by injury or atherosclerosis.",
    "title": "Prevention of tissue ischemia and related compositions",
    "abstract": "Provided herein are compositions for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival.",
    "domain": "A61"
  },
  {
    "statement_id": "RN200",
    "patent_id": "11529416",
    "claim": "An anti-VISTA antibody antagonist that blocks the immune checkpoint protein VISTA to activate anti-tumor immune responses in vivo, wherein combining the VISTA antagonist with a PD-L1 antagonist produces an additive reduction in tumor burden compared to either agent alone.",
    "title": "Vista modulators for diagnosis and treatment of cancer",
    "abstract": "The present disclosure relates to compositions and therapeutic methods for activating an immune response in a patient in need thereof. In a preferred embodiment, the subject methods and compositions are able to antagonize the activity of VISTA, a naturally occurring “checkpoint” protein which contributes to immune tolerance, optionally in combination with an antagonist of a second checkpoint pathway such as PD-1. For example, such methods and compositions may be suitable for preventing and treating colon cancer or another cancer. An exemplary VISTA antagonist, specifically, an anti-VISTA antibody, is demonstrated herein to activate an immune response against cancer cells in vitro and in vivo, thereby conferring protective anti-tumor immunity which decreased tumor burden. Additionally, an additive benefit was observed when a VISTA antagonist was used in combination with a second checkpoint protein antagonist, specifically, an antibody against PD-1 ligand (PD-L1).",
    "domain": "A61"
  },
  {
    "statement_id": "RN201",
    "patent_id": "11085069",
    "claim": "A microfluidic cartridge configured to accept a plurality of biological samples and perform PCR amplification on each sample individually or on multiple samples simultaneously within discrete microfluidic channels, enabling parallel polynucleotide amplification and detection in a single integrated device.",
    "title": "Microfluidic system for amplifying and detecting polynucleotides in parallel",
    "abstract": "The present technology provides for an apparatus for detecting polynucleotides in samples, particularly from biological samples. The technology more particularly relates to microfluidic systems that carry out PCR on nucleotides of interest within microfluidic channels, and detect those nucleotides. The apparatus includes a microfluidic cartridge that is configured to accept a plurality of samples, and which can carry out PCR on each sample individually, or a group of, or all of the plurality of samples simultaneously.",
    "domain": "A61"
  },
  {
    "statement_id": "RN202",
    "patent_id": "9975965",
    "claim": "Antibodies or antigen binding fragments that simultaneously bind to globo H, SSEA-3, and SSEA-4 glycan antigens on cancer cell surfaces, enabling both therapeutic targeting and diagnostic detection of carcinomas including breast, ovarian, lung, pancreatic, and prostate cancers.",
    "title": "Compositions and methods for treatment and detection of cancers",
    "abstract": "Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to globo H, SSEA3, and SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, skin, bone, lungs, breast, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervical, ovarian, and/or prostate cancer.",
    "domain": "A61"
  },
  {
    "statement_id": "RN203",
    "patent_id": "9630946",
    "claim": "Maleate salt forms of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide, including specific crystalline polymorphs thereof, prepared as pharmaceutical compositions for treating cancers driven by epidermal growth factor receptor family kinases.",
    "title": "Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof",
    "abstract": "The present invention relates to maleate salt forms of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide, methods of preparing crystalline maleate salt forms, the associated compounds, and pharmaceutical compositions containing the same. The maleate salts are useful in treating cancers, particularly those affected by kinases of the epidermal growth factor receptor family.",
    "domain": "A61"
  },
  {
    "statement_id": "RN204",
    "patent_id": "10093978",
    "claim": "Methods and compositions for selecting patients for treatment with a complement factor D inhibitor based on prognostic or predictive biomarkers comprising polymorphisms in complement factor H (CFH) and complement factor I (CFI) genes, wherein the presence of specific CFH/CFI polymorphisms predicts patient responsiveness to anti-factor D antibody treatment for age-related macular degeneration (AMD).",
    "title": "Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms",
    "abstract": "The invention provides methods and compositions for treating various degenerative diseases (e.g., AMD) with a factor D inhibitor (e.g., anti-factor D antibody or antigen-binding fragment thereof). Also provided are methods of selecting or identifying patients for treatment with a factor D inhibitor. Methods include the use of prognostic and/or predictive biomarkers.",
    "domain": "A61"
  },
  {
    "statement_id": "RN205",
    "patent_id": "10499652",
    "claim": "Synthetic combinations of agricultural plant seeds or seedlings with heterologous seed-derived bacterial endophytes, wherein purified populations of seed-origin bacterial endophytes isolated from cereal seeds are applied to confer agronomic benefits to the seed, seedling, or resulting plant.",
    "title": "Methods of use of seed-origin endophyte populations",
    "abstract": "This application relates to methods and materials for providing a benefit to a seed or seedling of an agricultural plant (e.g., an agricultural grass plant), or the agricultural plant derived from the seed or seedling. For example, this application provides purified bacterial populations that include novel seed-origin bacterial endophytes, and synthetic combinations of seeds and/or seedlings (e.g., cereal seeds and/or seedlings) with heterologous seed-derived bacterial endophytes.",
    "domain": "A61"
  },
  {
    "statement_id": "RN206",
    "patent_id": "9212212",
    "claim": "A CR2-FH fusion molecule comprising a complement receptor 2 (CR2) portion linked to a factor H (FH) portion, wherein the CR2 portion targets sites of complement activation and the FH portion inhibits the alternative complement pathway, for use in treating diseases such as age-related macular degeneration, rheumatoid arthritis, and ischemia reperfusion injury.",
    "title": "Targeting complement factor H for treatment of diseases",
    "abstract": "The invention provides a CR2-FH molecule comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising a CR2-FH molecule. Also provided are methods of using the compositions for treatment diseases in which the alternative complement pathway is implicated, such as age-related macular degeneration, rheumatoid arthritis, and ischemia reperfusion.",
    "domain": "A61"
  },
  {
    "statement_id": "RN207",
    "patent_id": "8231664",
    "claim": "A relatively non-invasive esophageal device configured to induce therapeutic hypothermia in a patient by circulating a temperature-controlled fluid through a catheter placed in the esophagus to transfer heat from the patient's core body, thereby treating ischemic conditions without requiring intravascular access.",
    "title": "Devices and methods for controlling patient temperature",
    "abstract": "Relatively non-invasive devices and methods for heating or cooling a patient's body are disclosed. Devices and methods for treating ischemic conditions by inducing therapeutic hypothermia are disclosed. Devices and methods for inducing therapeutic hypothermia through esophageal cooling are disclosed. Devices and methods for operative temperature management are disclosed.",
    "domain": "A61"
  },
  {
    "statement_id": "RN208",
    "patent_id": "9920134",
    "claim": "Monoclonal antibodies that specifically bind to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) and inhibit its activity, for use in treating hypercholesterolemia by reducing LDL cholesterol levels through blocking PCSK9-mediated degradation of LDL receptors.",
    "title": "Monoclonal antibodies to proprotein convertase subtilisin kexin type 9 (PCSK9)",
    "abstract": "Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.",
    "domain": "A61"
  },
  {
    "statement_id": "RN209",
    "patent_id": "8865672",
    "claim": "Blocking the interaction between thrombospondin-1 (TSP1) and CD47 receptor in blood vessels causes vasodilation and increases blood flow and tissue perfusion, thereby preventing tissue ischemia and damage under conditions of reduced blood flow such as those caused by injury or atherosclerosis.",
    "title": "Prevention of tissue ischemia and related methods",
    "abstract": "Provided herein are methods for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival.",
    "domain": "A61"
  },
  {
    "statement_id": "RN210",
    "patent_id": "10647676",
    "claim": "A bivalent linker molecule that simultaneously couples two or more chemical entities, specifically connecting targeting ligands such as vitamins to therapeutic drugs or diagnostic/imaging agents, enabling formation of conjugates that retain receptor-binding capability of the vitamin ligand while delivering the attached drug or diagnostic agent.",
    "title": "Bivalent linkers and conjugates thereof",
    "abstract": "This invention pertains to bivalent linkers, and the synthesis and use thereof. In particular, this invention pertains to the synthesis and use of bivalent linkers in preparing vitamin, drug, diagnostic agent, and/or imaging agent conjugates. The present invention includes divalent linkers, which are alternatively referred to as bivalent linkers, that may be used to couple, link, bond, attach, or otherwise associate two or more chemical entities. This coupling, linking, attachment, or association may be used in the formation of conjugates of such chemical entities. Those chemical entities include targeting ligands and receptor-binding ligands, such as vitamins. Those chemical entities also include drugs for treating various diseases or disease states, and imaging and diagnostic agents for diagnosing, detecting, or otherwise monitoring various diseases or disease states.",
    "domain": "A61"
  },
  {
    "statement_id": "RN211",
    "patent_id": "8901151",
    "claim": "(2S,3R)-N-(1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide bearing a (3-pyridinyl)methyl substituent at the nitrogen, wherein the specific stereochemical configuration (2S,3R) enables selective binding to and modulation of neuronal nicotinic acetylcholine receptors for treatment of central nervous system disorders.",
    "title": "Preparation and therapeutic applications of (2S, 3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]OCT-3-yl)-3,5-difluorobenzamide",
    "abstract": "The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS).",
    "domain": "A61"
  },
  {
    "statement_id": "RN212",
    "patent_id": "10202467",
    "claim": "A bifunctional fusion antibody comprising an anti-human insulin receptor antibody conjugated to α-L-Iduronidase enzyme, administered systemically to deliver therapeutically effective concentrations of α-L-Iduronidase across the blood-brain barrier into the CNS by exploiting insulin receptor-mediated transcytosis.",
    "title": "Methods and compositions for increasing α-L-iduronidase activity in the CNS",
    "abstract": "Provided herein are methods and compositions for treating a subject suffering from a deficiency in α-L-Iduronidase in the CNS. The methods include systemic administration of a bifunctional fusion antibody comprising an antibody to a human insulin receptor and an α-L-Iduronidase. A therapeutically effective systemic dose is based on the specific CNS uptake characteristics of human insulin receptor antibody-α-L-Iduronidase fusion antibodies as described herein.",
    "domain": "A61"
  },
  {
    "statement_id": "RN213",
    "patent_id": "10537573",
    "claim": "A pharmaceutical combination comprising a positive allosteric modulator (PAM) or orthosteric agonist of metabotropic glutamatergic receptor subtype 2 (mGluR2) together with a synaptic vesicle protein 2A (SV2A) ligand for therapeutic use.",
    "title": "Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use",
    "abstract": "The present invention relates to combinations comprising a positive allosteric modulator (“PAM”) of metabotropic glutamatergic receptor subtype 2 (“mGluR2”) or a pharmaceutically acceptable salt or a solvate thereof, or an orthosteric agonist of metabotropic glutamatergic receptor subtype 2 compound or a pharmaceutically acceptable salt or a solvate thereof, and a synaptic vesicle protein 2A (“SV2A”) ligand.",
    "domain": "A61"
  },
  {
    "statement_id": "RN214",
    "patent_id": "9828429",
    "claim": "A method of modifying the isoelectric point of an antibody while retaining antigen-binding activity by substituting at least one surface-exposed amino acid residue within the complementarity determining region (CDR) to alter the charge of that residue, enabling purification of multispecific antibodies and improvement of plasma pharmacokinetics.",
    "title": "Method of modifying isoelectric point of antibody via amino acid substitution in CDR",
    "abstract": "Provided are methods for modifying the isoelectric point of an antibody while retaining its antigen-binding activity, comprising modifying the charge of at least one exposable amino acid residue on the surface of the complementarity determining region (CDR). Also provided are methods for purifying multispecific antibodies, comprising modifying isoelectric point, and methods for improving the plasma pharmacokinetics of antibodies with a modified isoelectric point. Antibodies with a modified isoelectric point, pharmaceutical compositions comprising the antibodies as an active ingredient, and methods for producing the antibodies and compositions are also disclosed.",
    "domain": "A61"
  },
  {
    "statement_id": "RN215",
    "patent_id": "9289132",
    "claim": "A catheter balloon incorporating stretchable active integrated circuits and sensor arrays on its outer surface that maintain electrical functionality when the balloon is inflated, enabling direct contact measurement and therapy delivery against the inner wall of a body lumen.",
    "title": "Catheter balloon having stretchable integrated circuitry and sensor array",
    "abstract": "A system, device and method are presented for utilizing stretchable active integrated circuits with inflatable bodies. The invention allows for such operative features to come into direct contact with body structures, such as the inner wall of a lumen. Such direct contact increases accuracy of measurement and delivery of therapy.",
    "domain": "A61"
  },
  {
    "statement_id": "RN216",
    "patent_id": "9601671",
    "claim": "Optical systems comprising printable single-crystalline semiconductor elements assembled onto flexible or stretchable substrates via printing-based transfer techniques, achieving performance characteristics comparable to conventional high-temperature processed single-crystalline semiconductor devices while enabling flexible, conformable, and stretchable form factors not accessible by traditional fabrication methods.",
    "title": "Optical systems fabricated by printing-based assembly",
    "abstract": "Provided are optical devices and systems fabricated, at least in part, via printing-based assembly and integration of device components. In specific embodiments the present invention provides light emitting systems, light collecting systems, light sensing systems and photovoltaic systems comprising printable semiconductor elements, including large area, high performance macroelectronic devices. Optical systems of the present invention comprise semiconductor elements assembled, organized and/or integrated with other device components via printing techniques that exhibit performance characteristics and functionality comparable to single crystalline semiconductor based devices fabricated using conventional high temperature processing methods. Optical systems of the present invention have device geometries and configurations, such as form factors, component densities, and component positions, accessed by printing that provide a range of useful device functionalities. Optical systems of the present invention include devices and device arrays exhibiting a range of useful physical and mechanical properties including flexibility, shapeability, conformability and stretchablity.",
    "domain": "A61"
  },
  {
    "statement_id": "RN217",
    "patent_id": "9840505",
    "claim": "Crystalline polymorphic solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one, a PI3 kinase inhibitor, including specific processes for their preparation and pharmaceutical compositions thereof for treating diseases associated with PI3 kinase activity.",
    "title": "Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof",
    "abstract": "Polymorphs of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphs thereof, and pharmaceutical compositions thereof.",
    "domain": "A61"
  },
  {
    "statement_id": "RN218",
    "patent_id": "8226555",
    "claim": "An electrochemical analyte sensor comprising a substrate with a recessed channel formed therein and conductive material disposed within the recessed channel to form a working electrode, coupled to a wearable sensor control unit having conductive contacts that mate with corresponding contact pads on the sensor and a wireless transmitter that sends analyte measurement data to a separate display unit receiver for real-time analyte level indication.",
    "title": "Analyte monitoring device and methods of use",
    "abstract": "An analyte monitor includes a sensor, a sensor control unit, and a display unit. The sensor has, for example, a substrate, a recessed channel formed in the substrate, and conductive material disposed in the recessed channel to form a working electrode. The sensor control unit typically has a housing adapted for placement on skin and is adapted to receive a portion of an electrochemical sensor. The sensor control unit also includes two or more conductive contacts disposed on the housing and configured for coupling to two or more contact pads on the sensor. A transmitter is disposed in the housing and coupled to the plurality of conductive contacts for transmitting data obtained using the sensor. The display unit has a receiver for receiving data transmitted by the transmitter of the sensor control unit and a display coupled to the receiver for displaying an indication of a level of an analyte. The analyte monitor may also be part of a drug delivery system to alter the level of the analyte based on the data obtained using the sensor.",
    "domain": "A61"
  },
  {
    "statement_id": "RN219",
    "patent_id": "11186872",
    "claim": "A method of diagnosing inflammatory bowel disease (including Crohn's Disease, Ulcerative Colitis, and Medically Refractive Ulcerative Colitis) by detecting expression levels of RNASET2, TL1A, and/or IFN-γ as biomarkers, wherein the method further enables patient stratification and selection of therapeutically effective treatment agents based on the detected biomarker profiles.",
    "title": "Methods of diagnosing inflammatory bowel disease through RNASET2",
    "abstract": "Described herein are methods of diagnosing inflammatory bowel disease, including but not limited to Crohn's Disease (CD), Ulcerative Colitis (UC), and/or Medically Refractive Ulcerative Colitis (MR-UC), using RNA-SET2, TL1A and/or IFN-Y. The methods may comprise treating inflammatory bowel disease by administering a therapeutically effective amount of a therapeutic agent to a subject. Described further herein are processes for patient identification and/or stratification.",
    "domain": "A61"
  },
  {
    "statement_id": "RN220",
    "patent_id": "10049675",
    "claim": "A voice input processing system that identifies the speaking user and selects a personalized subset of a speech recognition vocabulary library based on that user's profile—including media items stored on the device, contact names, and frequently used applications—so that speech recognition is performed against this reduced, user-specific word subset rather than the full vocabulary library.",
    "title": "User profiling for voice input processing",
    "abstract": "This is directed to processing voice inputs received by an electronic device. In particular, this is directed to receiving a voice input and identifying the user providing the voice input. The voice input can be processed using a subset of words from a library used to identify the words or phrases of the voice input. The particular subset can be selected such that voice inputs provided by the user are more likely to include words from the subset. The subset of the library can be selected using any suitable approach, including for example based on the user's interests and words that relate to those interests. For example, the subset can include one or more words related to media items selected by the user for storage on the electronic device, names of the user's contacts, applications or processes used by the user, or any other words relating to the user's interactions with the device.",
    "domain": "A61"
  },
  {
    "statement_id": "RN221",
    "patent_id": "8428678",
    "claim": "A continuous analyte sensor system that uses one or more additional electrodes to measure a secondary analyte to obtain baseline or sensitivity measurements, which are then used to calibrate the primary continuous analyte sensor and can trigger events such as digital filtering or suspension of data display.",
    "title": "Calibration techniques for a continuous analyte sensor",
    "abstract": "Disclosed herein are systems and methods for calibrating a continuous analyte sensor, such as a continuous glucose sensor. One such system utilizes one or more electrodes to measure an additional analyte. Such measurements may provide a baseline or sensitivity measurement for use in calibrating the sensor. Furthermore, baseline and/or sensitivity measurements may be used to trigger events such as digital filtering of data or suspending display of data.",
    "domain": "A61"
  },
  {
    "statement_id": "RN222",
    "patent_id": "8366614",
    "claim": "An electrochemical analyte sensor comprising a substrate with a recessed channel formed therein and conductive material disposed within the recessed channel to form a working electrode, coupled to a skin-worn sensor control unit having conductive contacts that mate with contact pads on the sensor and a transmitter that wirelessly transmits sensor data to a remote display unit receiver.",
    "title": "Analyte monitoring device and methods of use",
    "abstract": "An analyte monitor includes a sensor, a sensor control unit, and a display unit. The sensor has, for example, a substrate, a recessed channel formed in the substrate, and conductive material disposed in the recessed channel to form a working electrode. The sensor control unit typically has a housing adapted for placement on skin and is adapted to receive a portion of an electrochemical sensor. The sensor control unit also includes two or more conductive contacts disposed on the housing and configured for coupling to two or more contact pads on the sensor. A transmitter is disposed in the housing and coupled to the plurality of conductive contacts for transmitting data obtained using the sensor. The display unit has a receiver for receiving data transmitted by the transmitter of the sensor control unit and a display coupled to the receiver for displaying an indication of a level of an analyte. The analyte monitor may also be part of a drug delivery system to alter the level of the analyte based on the data obtained using the sensor.",
    "domain": "A61"
  },
  {
    "statement_id": "RN223",
    "patent_id": "8728137",
    "claim": "A method for renal neuromodulation wherein thermal energy is applied directly or indirectly to renal neural fibers or their supplying vasculature to achieve neuromodulation, with sensor-based monitoring of neural fiber parameters, non-target tissue parameters, or thermal energy delivery element parameters to control the modulation, combined with protective elements that selectively reduce thermal damage to non-target tissues while preserving therapeutic effect on renal nerves.",
    "title": "Methods for thermally-induced renal neuromodulation",
    "abstract": "Methods and apparatus are provided for thermally-induced renal neuromodulation. Thermally-induced renal neuromodulation may be achieved via direct and/or via indirect application of thermal energy to heat or cool neural fibers that contribute to renal function, or of vascular structures that feed or perfuse the neural fibers. In some embodiments, parameters of the neural fibers, of non-target tissue, or of the thermal energy delivery element, may be monitored via one or more sensors for controlling the thermally-induced neuromodulation. In some embodiments, protective elements may be provided to reduce a degree of thermal damage induced in the non-target tissues.",
    "domain": "A61"
  },
  {
    "statement_id": "RN224",
    "patent_id": "10195235",
    "claim": "A method for treating ulcerative colitis comprising administering a pharmaceutical composition comprising live non-pathogenic fecal bacteria at least three times per week for at least 8 weeks to a subject with a Mayo endoscopy score of 3 or lower, without concomitant or immediately prior corticosteroid use.",
    "title": "Methods for treating ulcerative colitis",
    "abstract": "The present disclosure provides methods and treatment regimens for treating ulcerative colitis in a subject in need thereof. In particular, the methods described herein comprise treating a subject in need thereof with a treatment regimen comprising the administration of a pharmaceutical composition comprising live non-pathogenic fecal bacteria for at least 8 weeks and at least three times per week. In an aspect, the subject in need thereof exhibits a Mayo endoscopy score of 3 or lower. In some aspects, the subject in need thereof has no concomitant corticosteroid use during said method and has no corticosteroid use immediately prior to commencing said method.",
    "domain": "A61"
  },
  {
    "statement_id": "RN225",
    "patent_id": "9448172",
    "claim": "A method for identifying compounds that bind to or modulate a target by compartmentalizing individual compounds together with the target into microcapsules such that only a subset of the compound repertoire is represented in multiple copies within any single microcapsule, enabling screening of large molecular repertoires for drug lead identification.",
    "title": "Selection by compartmentalised screening",
    "abstract": "The invention describes a method for the identification of compounds which bind to a target component of a biochemical system or modulate the activity of the target, comprising the steps of: a.) compartmentalizing the compounds into microcapsules together with the target, such that only a subset of the repertoire is represented in multiple copies in any one microcapsules; and b.) identifying the compound which binds to or modulates the activity of the target. The invention enables the screening of large repertoires of molecules which can serve as leads for drug development.",
    "domain": "A61"
  },
  {
    "statement_id": "RN226",
    "patent_id": "9023037",
    "claim": "A balloon catheter apparatus for renal neuromodulation that delivers energy at multiple lengthwise and angularly offset positions within a renal artery to create overlapping less-than-full circumferential treatment zones that together define a non-continuous circumferential treatment pattern without forming a continuous circumferential lesion.",
    "title": "Balloon catheter apparatus for renal neuromodulation",
    "abstract": "Methods and apparatus are provided for non-continuous circumferential treatment of a body lumen. Apparatus may be positioned within a body lumen of a patient and may deliver energy at a first lengthwise and angular position to create a less-than-full circumferential treatment zone at the first position. The apparatus also may deliver energy at one or more additional lengthwise and angular positions within the body lumen to create less-than-full circumferential treatment zone(s) at the one or more additional positions that are offset lengthwise and angularly from the first treatment zone. Superimposition of the first treatment zone and the one or more additional treatment zones defines a non-continuous circumferential treatment zone without formation of a continuous circumferential lesion. Various embodiments of methods and apparatus for achieving such non-continuous circumferential treatment are provided.",
    "domain": "A61"
  },
  {
    "statement_id": "RN227",
    "patent_id": "10561631",
    "claim": "A method of reducing remnant lipoprotein cholesterol (RLP-C) in a subject comprising administering a pharmaceutical composition comprising eicosapentaenoic acid (EPA) or a derivative thereof, wherein the EPA treatment selectively lowers remnant lipoprotein particle cholesterol levels to reduce cardiovascular disease risk.",
    "title": "Methods of reducing RLP-C",
    "abstract": "In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.",
    "domain": "A61"
  },
  {
    "statement_id": "RN228",
    "patent_id": "9077695",
    "claim": "A system where a DNS-like IP address lookup request for a second device's identifier triggers a name service to simultaneously return the requested IP address, an availability indication for a secure communications service, and provisioning information for establishing an encrypted communication link, enabling the requesting device to use the lookup response itself to configure and initiate the encrypted connection.",
    "title": "System and method for establishing an encrypted communication link based on IP address lookup requests",
    "abstract": "A network device stores an application program for a secure communications service and has processor configured to execute the application program. The execution causes the processor to send a request to look up an internet protocol (IP) address of a second network device based on an identifier associated with the second network device, to receive, following a determination by a name service that the second network device is available for the secure communications service, the determination by the name service being based on the identifier in the request: (1) an indication that the second network device is available for the secure communications service, (2) the requested IP address of the second network device, and (3) provisioning information for an encrypted communication link. The execution further enables the processor to connect to the second network device and to communicate data with the second network via the encrypted communication link. The network device is a device at which a user uses the secure communications service to access the encrypted communication link.",
    "domain": "A61"
  },
  {
    "statement_id": "RN229",
    "patent_id": "8815275",
    "claim": "An implantable medical device coating comprising a first layer containing a therapeutic agent and an optional polymer, combined with a second layer containing a metallic material, wherein both layers are applied to a substrate such as an intravascular stent for localized drug delivery to body tissue.",
    "title": "Coatings for medical devices comprising a therapeutic agent and a metallic material",
    "abstract": "The invention relates generally to an implantable medical device for delivering a therapeutic agent to the body tissue of a patient, and a method for making such a medical device. In particular, the invention pertains to an implantable medical device, such as an intravascular stent, having a coating comprising a first coating composition comprising a therapeutic agent and, optionally, a polymer; and a second coating composition comprising a metallic material.",
    "domain": "A61"
  },
  {
    "statement_id": "RN230",
    "patent_id": "8880137",
    "claim": "An electrochemical analyte sensor comprising a substrate with a recessed channel formed therein and conductive material disposed within the recessed channel to form a working electrode, combined with a skin-worn sensor control unit having conductive contacts that couple to contact pads on the sensor and a transmitter that wirelessly transmits analyte data to a remote display unit receiver.",
    "title": "Analyte monitoring device and methods of use",
    "abstract": "An analyte monitor includes a sensor, a sensor control unit, and a display unit. The sensor has, for example, a substrate, a recessed channel formed in the substrate, and conductive material disposed in the recessed channel to form a working electrode. The sensor control unit typically has a housing adapted for placement on skin and is adapted to receive a portion of an electrochemical sensor. The sensor control unit also includes two or more conductive contacts disposed on the housing and configured for coupling to two or more contact pads on the sensor. A transmitter is disposed in the housing and coupled to the plurality of conductive contacts for transmitting data obtained using the sensor. The display unit has a receiver for receiving data transmitted by the transmitter of the sensor control unit and a display coupled to the receiver for displaying an indication of a level of an analyte. The analyte monitor may also be part of a drug delivery system to alter the level of the analyte based on the data obtained using the sensor.",
    "domain": "A61"
  },
  {
    "statement_id": "RN231",
    "patent_id": "10751342",
    "claim": "A method for treating cancer by first administering a Btk inhibitor to cause an increase or appearance of a specific lymphocyte subpopulation in blood (identified by immunophenotyping), then measuring biomarker expression profiles from that subpopulation, and selecting a second therapeutic agent based on the determined expression profile.",
    "title": "Use of inhibitors of Bruton's tyrosine kinase (Btk)",
    "abstract": "Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.",
    "domain": "A61"
  },
  {
    "statement_id": "RN232",
    "patent_id": "10918316",
    "claim": "A continuous analyte sensor calibration system that uses reference data from a short-term implanted continuous analyte sensor to initially calibrate or update sensor data from a long-term implanted continuous analyte sensor, and alternatively uses pre-insertion benchtop testing reference data to provide initial calibration of sensor data, employing matched sensor-reference data pairs evaluated for clinical acceptability and calibration quality.",
    "title": "System and methods for processing analyte sensor data for sensor calibration",
    "abstract": "Systems and methods for processing sensor analyte data are disclosed, including initiating calibration, updating calibration, evaluating clinical acceptability of reference and sensor analyte data, and evaluating the quality of sensor calibration. The sensor can be calibrated using a calibration set of one or more matched sensor and reference analyte data pairs. Reference data resulting from benchtop testing an analyte sensor prior to its insertion can be used to provide initial calibration of the sensor data. Reference data from a short term continuous analyte sensor implanted in a user can be used to initially calibrate or update sensor data from a long term continuous analyte sensor.",
    "domain": "A61"
  },
  {
    "statement_id": "RN233",
    "patent_id": "11350862",
    "claim": "A pre-connected analyte sensor assembly comprising a sensor carrier permanently attached to an analyte sensor prior to end-use deployment, wherein the sensor carrier includes both a substrate configured for mechanical coupling to testing, calibration, or wearable equipment and conductive contacts that electrically couple sensor electrodes to such equipment.",
    "title": "Pre-connected analyte sensors",
    "abstract": "Pre-connected analyte sensors are provided. A pre-connected analyte sensor includes a sensor carrier attached to an analyte sensor. The sensor carrier includes a substrate configured for mechanical coupling of the sensor to testing, calibration, or wearable equipment. The sensor carrier also includes conductive contacts for electrically coupling sensor electrodes to the testing, calibration, or wearable equipment.",
    "domain": "A61"
  },
  {
    "statement_id": "RN234",
    "patent_id": "8300669",
    "claim": "A laser control system employing multiphoton intrapulse interference phase scan (MIIPS) to characterize and compensate spectral phase distortions in ultrafast laser pulses, wherein a pulse shaper is positioned between a laser oscillator and the output of a laser amplifier to correct pulse distortions before amplification output.",
    "title": "Control system and apparatus for use with ultra-fast laser",
    "abstract": "A control system and apparatus for use with an ultra-fast laser is provided. In another aspect of the present invention, the apparatus includes a laser, pulse shaper, detection device and control system. A multiphoton intrapulse interference method is used to characterize the spectral phase of laser pulses and to compensate any distortions in an additional aspect of the present invention. In another aspect of the present invention, a system employs multiphoton intrapulse interference phase scan. Furthermore, another aspect of the present invention locates a pulse shaper and/or MIIPS unit between a laser oscillator and an output of a laser amplifier.",
    "domain": "A61"
  },
  {
    "statement_id": "RN235",
    "patent_id": "9012448",
    "claim": "1,2,4-triazolo[4,3-a]pyridine derivatives that function as positive allosteric modulators of metabotropic glutamate receptor subtype 2 (mGluR2), useful for treating neurological and psychiatric disorders associated with glutamate dysfunction.",
    "title": "1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors",
    "abstract": "The present invention relates to novel triazolo[4,3-a]pyridine derivatives of Formula (I)wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mGluR2”), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.",
    "domain": "A61"
  },
  {
    "statement_id": "RN236",
    "patent_id": "10675405",
    "claim": "A glucose monitoring system that awards scores or rewards to users based on interactions with the monitoring system interface—such as initiating displays, downloading data, and setting operational parameters—independently of the user's actual glucose measurement values, to incentivize engagement with the system.",
    "title": "Methods and systems for simulating glucose response to simulated actions",
    "abstract": "Methods and systems for encouraging interactions with a glucose monitoring system include incrementing a score and/or providing a reward based on a variety of different interactions with the glucose monitoring system. The interactions which improve the score may include initiating or changing displays, downloading data, setting operational parameters and other interactions that are independent of a user's glucose measurements. Encouraging these interactions can enhance success in maintaining healthy glucose concentrations.",
    "domain": "A61"
  },
  {
    "statement_id": "RN237",
    "patent_id": "10403012",
    "claim": "An integrated device combining a continuous glucose sensor receiver with a hand-held medicament injection pen, wherein the receiver electronics automatically calculate a bolus dose from continuous glucose sensor data and programmatically set that dose on the injection pen, which the user then manually administers, with the receiver and pen being either integrally formed or detachably connected via mutually engaging electrical contacts or wireless communication.",
    "title": "Integrated medicament delivery device for use with continuous analyte sensor",
    "abstract": "An integrated system for the monitoring and treating diabetes is provided, including an integrated receiver/hand-held medicament injection pen, including electronics, for use with a continuous glucose sensor. In some embodiments, the receiver is configured to receive continuous glucose sensor data, to calculate a medicament therapy (e.g., via the integrated system electronics) and to automatically set a bolus dose of the integrated hand-held medicament injection pen, whereby the user can manually inject the bolus dose of medicament into the host. In some embodiments, the integrated receiver and hand-held medicament injection pen are integrally formed, while in other embodiments they are detachably connected and communicated via mutually engaging electrical contacts and/or via wireless communication.",
    "domain": "A61"
  },
  {
    "statement_id": "RN238",
    "patent_id": "11517415",
    "claim": "A blood clot filter delivery system comprising an introducer and a push rod with a spline member having a main body and first and second boss portions longitudinally spaced apart to define a gap that retains an anchor member of the filter during intravascular delivery through the introducer.",
    "title": "Embolus blood clot filter and delivery system",
    "abstract": "A blood filter delivery system for delivering a filter into a vein includes an introducer and a push rod with a spline member disposed along the push rod. The spline member has a main body, and first and second boss portions spaced apart along the longitudinal axis to provide a gap for retaining anchor member of the filter during delivery via the introducer.",
    "domain": "A61"
  },
  {
    "statement_id": "RN239",
    "patent_id": "10311871",
    "claim": "A first electronic device that, upon sampling audio input through its microphone, sends stop instructions to a second external electronic device instructing it to forgo responding to audio input received through its own microphone, thereby coordinating which of multiple competing voice-triggered devices processes and responds to a detected audio input.",
    "title": "Competing devices responding to voice triggers",
    "abstract": "At a first electronic device with a display and a microphone: sampling audio input using the first microphone; in accordance with the sampling of audio input using the first microphone, sending stop instructions to a second electronic device with a second microphone, the second electronic device external to the first electronic device, wherein the second electronic device is configured to respond to audio input received using the second microphone, and wherein the stop instructions instruct the second electronic device to forgo responding to audio input received using the second microphone, wherein responding to audio input received using the second microphone comprises providing perceptible output.",
    "domain": "A61"
  },
  {
    "statement_id": "RN240",
    "patent_id": "8709817",
    "claim": "A flow cytometry particle sorting system comprising a microprocessor-based controller that dynamically varies the fluid delivery rate to the sorting system as a function of measured purity or yield of a target sub-population of particles, enabling real-time optimization of sorting performance through adaptive fluid flow control.",
    "title": "Systems and methods for sorting particles",
    "abstract": "A flow cytometry system and method for sorting a mixture of particles, such as a fluid switching sorting system for sorting selected particles which includes a control having a microprocessor programmed with instructions for implementing a control strategy for controlling the fluid delivery to the system to vary the rate at which fluid is delivered as a function of the purity or yield of a sub-population of particles.",
    "domain": "A61"
  },
  {
    "statement_id": "RN241",
    "patent_id": "10369175",
    "claim": "A pharmaceutical composition for treating chronic gastrointestinal diseases associated with abnormal microflora distribution, comprising viable non-pathogenic or attenuated pathogenic Clostridia combined with one or more additional viable microorganisms selected from Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi, formulated to recolonize the gastrointestinal tract of a mammalian host.",
    "title": "Probiotic recolonisation therapy",
    "abstract": "The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.",
    "domain": "A61"
  },
  {
    "statement_id": "RN242",
    "patent_id": "8757292",
    "claim": "A method for transmitting 10 kW or more of laser energy through a deep borehole while suppressing nonlinear optical phenomena that would otherwise degrade the high-power laser beam, enabling laser-based rock removal and borehole formation at depth within the earth.",
    "title": "Methods for enhancing the efficiency of creating a borehole using high power laser systems",
    "abstract": "Methods for utilizing 10 kW or more laser energy transmitted deep into the earth with the suppression of associated nonlinear phenomena to enhance the formation of Boreholes. Methods for the laser operations to reduce the critical path for forming a borehole in the earth. These methods can deliver high power laser energy down a deep borehole, while maintaining the high power to perform operations in such boreholes deep within the earth.",
    "domain": "A61"
  },
  {
    "statement_id": "RN243",
    "patent_id": "11306357",
    "claim": "A method for determining fetal chromosome ploidy status from a mixed maternal-fetal DNA sample by constructing a joint distribution model that generates expected allele distributions for each possible fetal ploidy state conditioned on parental genotypic data, then selecting the ploidy state whose expected allelic distribution pattern most closely matches the measured allelic distributions observed across a plurality of polymorphic loci in the mixed sample, wherein the sample is preferentially enriched at those polymorphic loci in a manner that minimizes allelic bias.",
    "title": "Methods for non-invasive prenatal ploidy calling",
    "abstract": "The present disclosure provides methods for determining the ploidy status of a chromosome in a gestating fetus from genotypic data measured from a sample of DNA from the mother of the fetus and from the fetus, and from genotypic data from the mother and optionally also from the father. The ploidy state is determined by using a joint distribution model to create a set of expected allele distributions for different possible fetal ploidy states given the parental genotypic data, and comparing the expected allelic distributions to the pattern of measured allelic distributions measured in the mixed sample, and choosing the ploidy state whose expected allelic distribution pattern most closely matches the observed allelic distribution pattern. In an embodiment, the mixed sample of DNA may be preferentially enriched at a plurality of polymorphic loci in a way that minimizes the allelic bias.",
    "domain": "A61"
  },
  {
    "statement_id": "RN244",
    "patent_id": "11246990",
    "claim": "An integrated system combining a continuous glucose sensor with a medicament delivery device, where an operable connection between components enables automated or semi-automated control of medicament delivery based on continuous glucose sensor data, reducing or eliminating required user input for determining the amount, type, and timing of medicament delivery.",
    "title": "Integrated delivery device for continuous glucose sensor",
    "abstract": "Systems and methods for integrating a continuous glucose sensor, including a receiver, a medicament delivery device, and optionally a single point glucose monitor are provided. Manual integrations provide for a physical association between the devices wherein a user (for example, patient or doctor) manually selects the amount, type, and/or time of delivery. Semi-automated integration of the devices includes integrations wherein an operable connection between the integrated components aids the user (for example, patient or doctor) in selecting, inputting, calculating, or validating the amount, type, or time of medicament delivery of glucose values, for example, by transmitting data to another component and thereby reducing the amount of user input required. Automated integration between the devices includes integrations wherein an operable connection between the integrated components provides for full control of the system without required user interaction.",
    "domain": "A61"
  },
  {
    "statement_id": "RN245",
    "patent_id": "11589823",
    "claim": "A glucose sensor monitoring system that detects transient non-glucose-related signal artifacts in a continuous glucose sensor data stream, determines artifact severity, and selectively applies distinct signal estimation algorithms or distinct parameter sets to replace corrupted data segments, thereby distinguishing and compensating for ischemia-, pH-, or temperature-induced noise from normal electronic or diffusion-related system noise.",
    "title": "Systems and methods for replacing signal artifacts in a glucose sensor data stream",
    "abstract": "Systems and methods for minimizing or eliminating transient non-glucose related signal noise due to non-glucose rate limiting phenomenon such as ischemia, pH changes, temperatures changes, and the like. The system monitors a data stream from a glucose sensor and detects signal artifacts that have higher amplitude than electronic or diffusion-related system noise. The system replaces some or the entire data stream continually or intermittently including signal estimation methods that particularly address transient signal artifacts. The system is also capable of detecting the severity of the signal artifacts and selectively applying one or more signal estimation algorithm factors responsive to the severity of the signal artifacts, which includes selectively applying distinct sets of parameters to a signal estimation algorithm or selectively applying distinct signal estimation algorithms.",
    "domain": "A61"
  },
  {
    "statement_id": "RN246",
    "patent_id": "8175673",
    "claim": "An electrochemical analyte sensor comprising a substrate with a recessed channel formed therein and conductive material disposed within the recessed channel to form a working electrode, coupled to a skin-mounted sensor control unit having conductive contacts that interface with corresponding contact pads on the sensor and a transmitter that wirelessly transmits sensor data to a remote display unit receiver for real-time analyte level indication.",
    "title": "Analyte monitoring device and methods of use",
    "abstract": "An analyte monitor includes a sensor, a sensor control unit, and a display unit. The sensor has, for example, a substrate, a recessed channel formed in the substrate, and conductive material disposed in the recessed channel to form a working electrode. The sensor control unit typically has a housing adapted for placement on skin and is adapted to receive a portion of an electrochemical sensor. The sensor control unit also includes two or more conductive contacts disposed on the housing and configured for coupling to two or more contact pads on the sensor. A transmitter is disposed in the housing and coupled to the plurality of conductive contacts for transmitting data obtained using the sensor. The display unit has a receiver for receiving data transmitted by the transmitter of the sensor control unit and a display coupled to the receiver for displaying an indication of a level of an analyte. The analyte monitor may also be part of a drug delivery system to alter the level of the analyte based on the data obtained using the sensor.",
    "domain": "A61"
  },
  {
    "statement_id": "RN247",
    "patent_id": "8293727",
    "claim": "A method of treating hypertriglyceridemia by administering a pharmaceutical composition comprising eicosapentaenoic acid (EPA) or a derivative thereof as the sole active ingredient, without docosahexaenoic acid (DHA), to reduce triglyceride levels in a subject in need thereof.",
    "title": "Methods of treating hypertriglyceridemia",
    "abstract": "In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.",
    "domain": "A61"
  },
  {
    "statement_id": "RN248",
    "patent_id": "11000213",
    "claim": "A continuous analyte sensor calibration system that uses reference data from a short-term implanted continuous analyte sensor to initially calibrate or update sensor data from a separately implanted long-term continuous analyte sensor, and that also uses pre-insertion benchtop testing reference data to provide initial calibration of in vivo sensor data.",
    "title": "System and methods for processing analyte sensor data for sensor calibration",
    "abstract": "Systems and methods for processing sensor analyte data are disclosed, including initiating calibration, updating calibration, evaluating clinical acceptability of reference and sensor analyte data, and evaluating the quality of sensor calibration. The sensor can be calibrated using a calibration set of one or more matched sensor and reference analyte data pairs. Reference data resulting from benchtop testing an analyte sensor prior to its insertion can be used to provide initial calibration of the sensor data. Reference data from a short term continuous analyte sensor implanted in a user can be used to initially calibrate or update sensor data from a long term continuous analyte sensor.",
    "domain": "A61"
  },
  {
    "statement_id": "RN249",
    "patent_id": "8480580",
    "claim": "An electrochemical analyte sensor comprising a substrate with a recessed channel formed therein and conductive material disposed within the recessed channel to form a working electrode, coupled to a wearable sensor control unit having conductive contacts that mate with contact pads on the sensor and a transmitter that wirelessly transmits sensor data to a remote display unit receiver showing analyte levels.",
    "title": "Analyte monitoring device and methods of use",
    "abstract": "An analyte monitor includes a sensor, a sensor control unit, and a display unit. The sensor has, for example, a substrate, a recessed channel formed in the substrate, and conductive material disposed in the recessed channel to form a working electrode. The sensor control unit typically has a housing adapted for placement on skin and is adapted to receive a portion of an electrochemical sensor. The sensor control unit also includes two or more conductive contacts disposed on the housing and configured for coupling to two or more contact pads on the sensor. A transmitter is disposed in the housing and coupled to the plurality of conductive contacts for transmitting data obtained using the sensor. The display unit has a receiver for receiving data transmitted by the transmitter of the sensor control unit and a display coupled to the receiver for displaying an indication of a level of an analyte. The analyte monitor may also be part of a drug delivery system to alter the level of the analyte based on the data obtained using the sensor.",
    "domain": "A61"
  },
  {
    "statement_id": "RN250",
    "patent_id": "8900292",
    "claim": "An implantable medical device such as an intravascular stent having a coating with increased surface area that includes at least one coating composition with both an exposed abluminal surface and an exposed luminal surface or exposed side surface, configured to enhance therapeutic agent delivery to body tissue.",
    "title": "Coating for medical device having increased surface area",
    "abstract": "Described herein are implantable medical devices for delivering a therapeutic agent to the body tissue of a patient, and methods for making such medical devices. In particular, the implantable medical devices, such as intravascular stents, have a coating which includes at least one coating composition and has an exposed abluminal surface and an exposed luminal surface or exposed side surface.",
    "domain": "A61"
  },
  {
    "statement_id": "RN251",
    "patent_id": "11008590",
    "claim": "A DNA-targeting RNA comprising a targeting sequence that, together with an enzymatically inactive Cas9 polypeptide, enables site-specific modulation of transcription at a target DNA locus without cleaving the DNA, wherein the RNA-directed targeting specificity is determined by the targeting sequence complementarity to the target DNA.",
    "title": "Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription",
    "abstract": "The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.",
    "domain": "C12"
  },
  {
    "statement_id": "RN252",
    "patent_id": "9973940",
    "claim": "A guided wave launcher system with dynamic impedance matching wherein a mismatch probe detects impedance mismatch from an output RF signal, and a controller adjusts one or more variable circuit elements in an impedance matching circuit to reduce the mismatch, enabling a guided electromagnetic wave to propagate along a transmission medium surface at a non-optical carrier frequency without requiring an electrical return path.",
    "title": "Apparatus and methods for dynamic impedance matching of a guided wave launcher",
    "abstract": "Aspects of the subject disclosure may include, for example, a guided wave launcher generates, in response to an output RF signal, a guided electromagnetic wave along a surface of a transmission medium, wherein the guided electromagnetic wave propagates along the surface of the transmission medium without requiring an electrical return path, and wherein the guided electromagnetic wave has a non-optical carrier frequency. A mismatch probe generates a mismatch signal based on the output RF signal, wherein the mismatch signal indicates an impedance mismatch of the guided wave launcher. A controller generates one or more control signals in response to the mismatch signal, wherein the one or more control signals adjust one or more adjustable circuit elements of an impedance matching circuit, wherein adjustment of the one or more adjustable circuit elements facilitates reducing the impedance mismatch of the guided wave launcher. Other embodiments are disclosed.",
    "domain": "C12"
  },
  {
    "statement_id": "RN253",
    "patent_id": "10200094",
    "claim": "A distributed-input distributed-output (DIDO) system employing M spatially distributed transmit antennas that uses block diagonalization (BD) precoding with channel state information (CSI) to simultaneously create up to (M−1) spatial nulls of zero RF energy at specific receiver locations, where the CSI is either fed back from receivers or computed at the transmitter via channel reciprocity.",
    "title": "Interference management, handoff, power control and link adaptation in distributed-input distributed-output (DIDO) communication systems",
    "abstract": "A system and method are described herein employing a plurality of distributed transmitting antennas to create locations in space with zero RF energy. In one embodiment, when M transmit antennas are employed, it is possible to create up to (M−1) points of zero RF energy in predefined locations. In one embodiment of the invention, the points of zero RF energy are wireless devices and the transmit antennas are aware of the channel state information (CSI) between the transmitters and the receivers. In one embodiment, the CSI is computed at the receivers and fed back to the transmitters. In another embodiment, the CSI is computed at the transmitter via training from the receivers, assuming channel reciprocity is exploited. The transmitters may utilize the CSI to determine the interfering signals to be simultaneously transmitted. In one embodiment, block diagonalization (BD) precoding is employed at the transmit antennas to generate points of zero RF energy.",
    "domain": "C12"
  },
  {
    "statement_id": "RN254",
    "patent_id": "11492727",
    "claim": "A variegated nucleic acid library comprising multiple nucleic acid sequences each encoding a predetermined variant of at least one reference nucleic acid sequence, wherein the variants encode scaffold proteins comprising a GLP1R (glucagon-like peptide-1 receptor) binding domain, enabling systematic exploration of sequence space for GLP1R-binding protein engineering.",
    "title": "Variant nucleic acid libraries for GLP1 receptor",
    "abstract": "Provided herein are methods and compositions relating to glucagon-like peptide-1 receptor (GLP1R) libraries having nucleic acids encoding for a scaffold comprising a GLP1R binding domain. Libraries described herein include variegated libraries comprising nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence. Further described herein are protein libraries generated when the nucleic acid libraries are translated. Further described herein are cell libraries expressing variegated nucleic acid libraries described herein.",
    "domain": "C12"
  },
  {
    "statement_id": "RN255",
    "patent_id": "10676759",
    "claim": "A DNA-targeting RNA comprising a targeting sequence that, together with a site-specific modifying polypeptide (Cas9), directs site-specific modification of a target DNA, wherein an enzymatically inactive Cas9 polypeptide complexed with the DNA-targeting RNA modulates transcription of a target nucleic acid without cleaving the DNA.",
    "title": "Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription",
    "abstract": "The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.",
    "domain": "C12"
  },
  {
    "statement_id": "RN256",
    "patent_id": "10918853",
    "claim": "A topical nerve stimulator system comprising a dermal patch with an integrated electrical signal generator, a wireless signal receiver for activating the generator, and an on-patch power source, enabling transcutaneous neurological stimulation without implanted components.",
    "title": "Topical neurological stimulation",
    "abstract": "A topical nerve stimulator patch and system are provided comprising a dermal patch; an electrical signal generator associated with the patch; a signal receiver to activate the electrical signal generator; a power source for the electrical signal generator associated with the patch and an electrical signal activation device.",
    "domain": "C12"
  },
  {
    "statement_id": "RN257",
    "patent_id": "9445867",
    "claim": "A method for renal neuromodulation using monopolar pulsed electric field delivery via intravascular catheters with expandable treatment members to effectuate irreversible electroporation of renal neural fibers, optionally performed bilaterally on both renal arteries simultaneously.",
    "title": "Methods for renal neuromodulation via catheters having expandable treatment members",
    "abstract": "Methods and apparatus are provided for monopolar neuromodulation, e.g., via a pulsed electric field. Such monopolar neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, monopolar neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such monopolar neuromodulation is performed bilaterally.",
    "domain": "C12"
  },
  {
    "statement_id": "RN258",
    "patent_id": "10020844",
    "claim": "A broadcast communication system that transmits an outage status signal to user devices via guided electromagnetic waves along a transmission medium in response to detecting a power outage, where the waves propagate without utilizing an electrical return path.",
    "title": "Method and apparatus for broadcast communication via guided waves",
    "abstract": "Aspects of the subject disclosure may include, for example, a broadcast communication system that is operable to detect a first power outage. A first plurality of electromagnetic waves is generated for transmission to a plurality of user devices of the broadcast communication system via a guided wave transceiver, where the first plurality of electromagnetic waves includes an outage status signal generated in response to detecting the first power outage, and where the first plurality of electromagnetic waves is guided by at least one transmission medium and propagates without utilizing an electrical return path. Other embodiments are disclosed.",
    "domain": "C12"
  },
  {
    "statement_id": "RN259",
    "patent_id": "9911020",
    "claim": "A device that receives a personal identifier from an RFID tag via a first wireless signal, then re-transmits that identifier combined with location information as electromagnetic waves coupled into a transmission medium at a first physical interface, where the waves propagate without requiring an electrical return path and are guided to a receiving device at a second physical interface of the transmission medium.",
    "title": "Method and apparatus for tracking via a radio frequency identification device",
    "abstract": "Aspects of the subject disclosure may include, for example, a device, including a radio frequency interface configured to receive, from a radio frequency identification device, a first wireless signal of a first carrier frequency that indicates a personal identifier. A transceiver can be configured to generate a transmission signal of second carrier frequency that indicates the personal identifier and location information associated with the device and to transmit electromagnetic waves in response to the transmission signal at a first physical interface of a transmission medium that propagate without requiring an electrical return path. The electromagnetic waves are guided by the transmission medium and are received by a receiving device at a second physical interface of the transmission medium, and the transmission signal can be extracted from the electromagnetic waves by the receiving device. Other embodiments are disclosed.",
    "domain": "C12"
  },
  {
    "statement_id": "RN260",
    "patent_id": "10301651",
    "claim": "A DNA-targeting RNA comprising a targeting sequence that, together with an enzymatically inactive Cas9 polypeptide, provides site-specific modulation of transcription of a target DNA without cleaving the DNA, enabling RNA-directed transcriptional regulation at a sequence-specific genomic locus.",
    "title": "Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription",
    "abstract": "The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.",
    "domain": "C12"
  },
  {
    "statement_id": "RN261",
    "patent_id": "9914924",
    "claim": "Methods and compositions for delivering iRNA agents (interfering RNA) specifically to neural cells to treat neurological diseases, wherein the iRNA agents silence disease-associated gene expression in the nervous system.",
    "title": "Methods and compositions for treating neurological disease",
    "abstract": "This invention relates to methods and compositions for treating neurological disease, and more particularly to methods of delivering iRNA agents to neural cells for the treatment of neurological diseases.",
    "domain": "C12"
  },
  {
    "statement_id": "RN262",
    "patent_id": "10064269",
    "claim": "A multilayer stretchable electronic device in which a neutral mechanical surface is positioned coincident or proximate to a functional device layer susceptible to strain-induced failure by incorporating one or more layers with spatially inhomogeneous properties achieved through patterning, thereby providing strain isolation to the functional layer during stretching, compression, or flexing.",
    "title": "Stretchable and foldable electronic devices",
    "abstract": "Disclosed herein are stretchable, foldable and optionally printable, processes for making devices and devices such as semiconductors, electronic circuits and components thereof that are capable of providing good performance when stretched, compressed, flexed or otherwise deformed. Strain isolation layers provide good strain isolation to functional device layers. Multilayer devices are constructed to position a neutral mechanical surface coincident or proximate to a functional layer having a material that is susceptible to strain-induced failure. Neutral mechanical surfaces are positioned by one or more layers having a property that is spatially inhomogeneous, such as by patterning any of the layers of the multilayer device.",
    "domain": "C12"
  },
  {
    "statement_id": "RN263",
    "patent_id": "10069185",
    "claim": "A system that directs electromagnetic waves to an interface of a transmission medium to induce propagation of electromagnetic waves having at least a dominant non-fundamental wave mode, as opposed to the fundamental TEM mode, along the transmission medium.",
    "title": "Methods and apparatus for inducing a non-fundamental wave mode on a transmission medium",
    "abstract": "Aspects of the subject disclosure may include, for example, a system for generating first electromagnetic waves and directing instances of the first electromagnetic waves to an interface of a transmission medium to induce propagation of second electromagnetic waves having at least a dominant non-fundamental wave mode. Other embodiments are disclosed.",
    "domain": "C12"
  },
  {
    "statement_id": "RN264",
    "patent_id": "8658430",
    "claim": "A microfluidic method for manipulating droplet size in real-time by dynamically adjusting the pressure exerted on either the aqueous fluid or the immiscible carrier fluid during the droplet formation step, enabling active control of droplet volume without changing channel geometry or fluid flow rates.",
    "title": "Manipulating droplet size",
    "abstract": "The invention generally relates to methods and systems for manipulating droplet size. In certain aspects, the invention provides methods for manipulating droplet size that include forming droplets of aqueous fluid surrounded by an immiscible carrier fluid, and manipulating droplet size during the forming step by adjusting pressure exerted on the aqueous fluid or the carrier fluid.",
    "domain": "C12"
  },
  {
    "statement_id": "RN265",
    "patent_id": "8129155",
    "claim": "A non-naturally occurring microbial organism engineered with at least one exogenous nucleic acid encoding pathway enzymes that enable conversion of syngas (CO, CO2, H2) as a carbon and energy source to isopropanol, 4-hydroxybutyrate, or 1,4-butanediol through heterologous metabolic pathways expressed at sufficient levels to produce these target chemicals.",
    "title": "Microorganisms and methods for conversion of syngas and other carbon sources to useful products",
    "abstract": "A non-naturally occurring microbial organism having an isopropanol, 4-hydroxybutryate, or 1,4-butanediol pathway includes at least one exogenous nucleic acid encoding an isopropanol, 4-hydroxybutryate, or 1,4-butanediol pathway enzyme expressed in a sufficient amount to produce isopropanol, 4-hydroxybutryate, or 1,4-butanediol. The aforementioned organisms are cultured to produce isopropanol, 4-hydroxybutryate, or 1,4-butanediol.",
    "domain": "C12"
  },
  {
    "statement_id": "RN266",
    "patent_id": "10138465",
    "claim": "A method for differentiating pluripotent stem cells into pancreatic endoderm cells expressing PDX1, NKX6.1, and HB9 by culturing Stage 4 to Stage 6 cells with a thyroid hormone (T3), an ALK5 inhibitor, or a combination of both to promote pancreatic endocrine differentiation.",
    "title": "Differentiation of human embryonic stem cells into pancreatic endocrine cells using HB9 regulators",
    "abstract": "The present invention provides methods to promote differentiation of pluripotent stem cells to pancreatic endoderm cells expressing PDX1, NKX6.1, and HB9. In particular, the methods encompass culturing Stage 4 to Stage 6 cells with a thyroid hormone (e.g. T3), an ALK5 inhibitor, or both.",
    "domain": "C12"
  },
  {
    "statement_id": "RN267",
    "patent_id": "11141257",
    "claim": "A blood clot filter delivery system comprising a push-rod with a spline member having first and second boss portions spaced apart along a longitudinal axis to define a gap that retains filter anchor members during delivery, enabling the same single delivery system to introduce the filter into a vein from either femoral or jugular access without modification. The filter includes first and second filter structures diverging in opposite directions, connected by a link that allows each structure to be independently collapsed into a generally cylindrical shape for retrieval.",
    "title": "Embolus blood clot filter utilizable with a single delivery system or a single retrieval system in one of a femoral or jugular access",
    "abstract": "A blood filter delivery system for delivering a filter into a vein from either a femoral or jugular access. The preferred system includes an introducer and a push-rod with a spline member disposed along the push-rod and a pusher member disposed on a distal end. The spline member has a main body, first and second boss portions spaced apart along the longitudinal axis to provide a gap for retaining anchor members of the filter during delivery via the introducer. In an alternative embodiment, a preferred filter includes first and second filter structures diverging in opposite directions. A link is connected to portions of each of the first and second filter structures so that each filter structure can be independently collapsed into a generally cylindrical shape.",
    "domain": "C12"
  },
  {
    "statement_id": "RN268",
    "patent_id": "10988780",
    "claim": "A DNA-targeting RNA comprising a targeting sequence that, together with an enzymatically inactive Cas9 polypeptide, enables site-specific modification of a target DNA or modulation of transcription at a specific genomic locus without cleaving the DNA, where the targeting sequence directs the Cas9 polypeptide to the target site via RNA-directed sequence complementarity.",
    "title": "Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription",
    "abstract": "The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.",
    "domain": "C12"
  },
  {
    "statement_id": "RN269",
    "patent_id": "10431204",
    "claim": "A method for identifying trending terms absent from or underrepresented in a speech recognizer vocabulary by monitoring electronic data sources (social networks, news feeds, search queries) for candidate terms, then searching archived speech audio using open-vocabulary spoken term detection to find phonetic matches, and generating notifications with usage statistics and context when candidates are confirmed in live speech traffic.",
    "title": "Method and apparatus for discovering trending terms in speech requests",
    "abstract": "Systems and processes are disclosed for discovering trending terms in automatic speech recognition. Candidate terms (e.g., words, phrases, etc.) not yet found in a speech recognizer vocabulary or having low language model probability can be identified based on trending usage in a variety of electronic data sources (e.g., social network feeds, news sources, search queries, etc.). When candidate terms are identified, archives of live or recent speech traffic can be searched to determine whether users are uttering the candidate terms in dictation or speech requests. Such searching can be done using open vocabulary spoken term detection to find phonetic matches in the audio archives. As the candidate terms are found in the speech traffic, notifications can be generated that identify the candidate terms, provide relevant usage statistics, identify the context in which the terms are used, and the like.",
    "domain": "C12"
  },
  {
    "statement_id": "RN270",
    "patent_id": "9620104",
    "claim": "A method that receives speech input containing a word, determines a first phonetic representation using a speech recognition phonetic alphabet, then maps that first set of phonemes to a second set of phonemes from a speech synthesis phonetic alphabet, and stores the resulting second phonetic representation in association with the word's text string to enable user-specified pronunciation for both speech recognition and synthesis.",
    "title": "System and method for user-specified pronunciation of words for speech synthesis and recognition",
    "abstract": "The method is performed at an electronic device with one or more processors and memory storing one or more programs for execution by the one or more processors. A first speech input including at least one word is received. A first phonetic representation of the at least one word is determined, the first phonetic representation comprising a first set of phonemes selected from a speech recognition phonetic alphabet. The first set of phonemes is mapped to a second set of phonemes to generate a second phonetic representation, where the second set of phonemes is selected from a speech synthesis phonetic alphabet. The second phonetic representation is stored in association with a text string corresponding to the at least one word.",
    "domain": "C07"
  },
  {
    "statement_id": "RN271",
    "patent_id": "10936953",
    "claim": "A DNA-based digital information storage device comprising addressable sidewall electrodes that locally control polynucleotide synthesis steps—including deprotection, extension, and cleavage—to enable spatially selective writing of digital information into DNA sequences at high storage density.",
    "title": "DNA-based digital information storage with sidewall electrodes",
    "abstract": "Provided herein are compositions, devices, systems and methods for generation and use of biomolecule-based information for storage. Further provided are devices-having addressable electrodes controlling polynucleotide synthesis (deprotection, extension, or cleavage, etc.) The compositions, devices, systems and methods described herein provide improved storage, density, and retrieval of biomolecule-based information.",
    "domain": "C07"
  },
  {
    "statement_id": "RN272",
    "patent_id": "10987648",
    "claim": "A process for differential functionalization of a surface to support biopolymer synthesis that uses lamps, lasers, and/or microcontact printing to selectively add functional groups to defined regions of a surface, enabling efficient and uniform oligonucleic acid synthesis on the functionalized substrate.",
    "title": "Functionalized surfaces and preparation thereof",
    "abstract": "Compositions, devices, methods and systems are provided for differential functionalization of a surface of a structure to support biopolymer synthesis. Provided herein are processes which include use of lamps, lasers, and/or microcontact printing to add functional groups to surfaces for the efficient and uniform synthesis of oligonucleic acids.",
    "domain": "C07"
  },
  {
    "statement_id": "RN273",
    "patent_id": "8076292",
    "claim": "A method for remodeling Factor VIII by enzymatically adding, deleting, or modifying glycosyl groups on the protein and conjugating a modifying group (such as PEG or therapeutic agent) to Factor VIII through glycosyl linkages to alter its pharmacological properties.",
    "title": "Factor VIII: remodeling and glycoconjugation of factor VIII",
    "abstract": "The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.",
    "domain": "C07"
  },
  {
    "statement_id": "RN274",
    "patent_id": "10745742",
    "claim": "Gel beads are functionalized with barcode molecules generated through two or more sequential ligation reactions in a combinatorial fashion, where each barcode molecule comprises a barcode sequence and a functional sequence, enabling a single bead to carry two or more different barcode molecules for multi-analyte analysis including nucleic acids, proteins, and perturbation agents.",
    "title": "Functionalized gel beads",
    "abstract": "The present disclosure provides methods of generating supports (e.g., beads) comprising barcode molecules coupled thereto. A barcode molecule coupled to a support may comprise a barcode sequence and a functional sequence. A barcode molecule may be generated using two or more ligation reactions in a combinatorial fashion. A support comprising two or more different barcode molecules may be useful for analyzing or processing one or more analytes such as nucleic acid molecules, proteins, and/or perturbation agents.",
    "domain": "C07"
  },
  {
    "statement_id": "RN275",
    "patent_id": "10143748",
    "claim": "Methods for B-cell reduction using a synergistic combination of CD37-specific binding molecules and CD20-specific binding molecules, wherein the co-administration of these two distinct B-cell surface antigen-targeting agents achieves greater B-cell depletion than either agent alone for treatment of diseases involving aberrant B-cell activity.",
    "title": "B-cell reduction using CD37-specific and CD20-specific binding molecules",
    "abstract": "The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.",
    "domain": "C07"
  },
  {
    "statement_id": "RN276",
    "patent_id": "8612159",
    "claim": "An analyte monitoring device comprising an electrochemical sensor with a substrate having a recessed channel containing conductive material forming a working electrode, coupled to a skin-mountable sensor control unit that wirelessly transmits analyte data via conductive contacts mating with sensor contact pads to a remote display unit.",
    "title": "Analyte monitoring device and methods of use",
    "abstract": "An analyte monitor includes a sensor, a sensor control unit, and a display unit. The sensor has, for example, a substrate, a recessed channel formed in the substrate, and conductive material disposed in the recessed channel to form a working electrode. The sensor control unit typically has a housing adapted for placement on skin and is adapted to receive a portion of an electrochemical sensor. The sensor control unit also includes two or more conductive contacts disposed on the housing and configured for coupling to two or more contact pads on the sensor. A transmitter is disposed in the housing and coupled to the plurality of conductive contacts for transmitting data obtained using the sensor. The display unit has a receiver for receiving data transmitted by the transmitter of the sensor control unit and a display coupled to the receiver for displaying an indication of a level of an analyte.",
    "domain": "C07"
  },
  {
    "statement_id": "RN277",
    "patent_id": "9309296",
    "claim": "A vector delivering a light-activated ion channel or pump molecule comprising a nucleic acid sequence encoding a modified light-activated molecule, wherein the modification is located near the all-trans retinal Schiff base to extend the duration of the open state of the channel relative to the wild-type molecule.",
    "title": "Optically-based stimulation of target cells and modifications thereto",
    "abstract": "Stimulation of target cells using light, e.g., in vivo or in vitro, is implemented using a variety of methods and devices. One example involves a vector for delivering a light-activated molecule comprising a nucleic acid sequence that codes for light-activated molecule. The light-activated molecule includes a modification to a location near the all-trans retinal Schiff base, e.g., to extends the duration time of the open state. Other aspects and embodiments are directed to systems, methods, kits, compositions of matter and molecules for ion channels or pumps or for controlling currents in a cell (e.g., in vivo or in vitro environments).",
    "domain": "C07"
  },
  {
    "statement_id": "RN278",
    "patent_id": "11174257",
    "claim": "Specific salt forms of the FGFR inhibitor compound 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidin-2-one, including their methods of preparation, wherein these salts are useful for treating FGFR-mediated diseases such as cancer.",
    "title": "Salts of an FGFR inhibitor",
    "abstract": "The present invention relates to salt forms of the Fibroblast Growth Factor Receptors (FGFR) inhibitor 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidin-2-one, including methods of preparation thereof, where the compound is useful in the treatment of FGFR mediated diseases such as cancer.",
    "domain": "C07"
  },
  {
    "statement_id": "RN279",
    "patent_id": "8889399",
    "claim": "A non-naturally occurring microbial organism engineered with a complete biosynthetic pathway for 1,4-butanediol production from α-ketoglutarate, comprising exogenous nucleic acids encoding α-ketoglutarate decarboxylase, 4-hydroxybutanoate dehydrogenase, 4-hydroxybutyryl-CoA transferase or butyrate kinase/phosphotransbutyrylase, aldehyde dehydrogenase, and alcohol dehydrogenase, enabling anaerobic fermentative production of 1,4-BDO via a 4-hydroxybutanoic acid intermediate.",
    "title": "Compositions and methods for the biosynthesis of 1,4-butanediol and its precursors",
    "abstract": "The invention provides a non-naturally occurring microbial organism having 4-hydroxybutanoic acid (4-HB) and 1,4-butanediol (1,4-BDO) biosynthetic pathways. The pathways include exogenous nucleic acids encoding a) an α-ketoglutarate decarboxylase; b) a 4-hydroxybutanoate dehydrogenase; c) a 4-hydroxybutyryl-CoA:acetyl-CoA transferase or a butyrate kinase and a phosphotransbutyrylase; d) an aldehyde dehydrogenase, and e) an alcohol dehydrogenase, wherein the exogenous nucleic acids are expressed in sufficient amounts to produce 1,4-butanediol (1,4-BDO). Also provide is a method for the production of 1,4-BDO. The method includes culturing the non-naturally occurring microbial organism having 4-HB and 1,4-BDO biosynthetic pathways substantially anaerobic conditions for a sufficient period of time to produce 1,4-BDO.",
    "domain": "C07"
  },
  {
    "statement_id": "RN280",
    "patent_id": "10280192",
    "claim": "A method for synthesizing oligonucleotides comprising phosphorothiotriester linkages by reacting an H-phosphonate with a silylating reagent to generate a silyloxyphosphonate intermediate, then reacting the silyloxyphosphonate with a thiosulfonate reagent to directly install the phosphorothiotriester linkage, enabling functionalized nucleic acid synthesis without conventional phosphoramidite chemistry.",
    "title": "Methods for the synthesis of functionalized nucleic acids",
    "abstract": "The present application, among other things, provides technologies, e.g., reagents, methods, etc. for preparing oligonucleotides comprising phosphorothiotriesters linkages. In some embodiments, provided methods comprise reacting an H-phosphonate of structure Ia or Ib with a silylating reagent to provide a silyloxyphosphonate, and reacting the silyloxyphosphonate with a thiosulfonate reagent of structure IIa or IIb to provide an oligonucleotide of structure IIIa or IIIb. In some embodiments, provided methods comprise reacting an H-phosphonate of structure Ic with a silylating reagent to provide a silyloxyphosphonate, reacting the silyloxyphosphonate with a bis(thiosulfonate) reagent of structure IVc to provide a phosphorothiotriester comprising a thiosulfonate group of structure Vc, and then reacting the phosphorothiotriester comprising a thiosulfonate group of structure Vc with a nucleophile of structure VIc to provide an oligonucleotide of structure IIIc. In some embodiments, the present application provides a thiosulfonate reagent of structure IIa:",
    "domain": "C07"
  },
  {
    "statement_id": "RN281",
    "patent_id": "9068213",
    "claim": "Recombinant oleaginous cells engineered by manipulating genes encoding stearoyl-ACP desaturase, delta-12 fatty acid desaturase, acyl-ACP thioesterase, ketoacyl-ACP synthase, and lysophosphatidic acid acyltransferase to produce triglyceride oils with specified fatty acid profiles and regiospecific/stereospecific profiles, including saturated-unsaturated-saturated triglyceride enrichment or mid-chain fatty acid enrichment, for applications such as frying oils, shortenings, cocoa butter replacements, and industrial lubricants.",
    "title": "Microorganisms expressing ketoacyl-CoA synthase and uses thereof",
    "abstract": "Recombinant DNA techniques are used to produce oleaginous recombinant cells that produce triglyceride oils having desired fatty acid profiles and regiospecific or stereospecific profiles. Genes manipulated include those encoding stearoyl-ACP desturase, delta 12 fatty acid desaturase, acyl-ACP thioesterase, ketoacyl-ACP synthase, and lysophosphatidic acid acyltransferase. The oil produced can have enhanced oxidative or thermal stability, or can be useful as a frying oil, shortening, roll-in shortening, tempering fat, cocoa butter replacement, as a lubricant, or as a feedstock for various chemical processes. The fatty acid profile can be enriched in midchain profiles or the oil can be enriched in triglycerides of the saturated-unsaturated-saturated type.",
    "domain": "C07"
  },
  {
    "statement_id": "RN282",
    "patent_id": "9200307",
    "claim": "Oleaginous recombinant cells are engineered by manipulating genes encoding stearoyl-ACP desaturase, delta-12 fatty acid desaturase, acyl-ACP thioesterase, ketoacyl-ACP synthase, and lysophosphatidic acid acyltransferase to produce triglyceride oils with predetermined fatty acid profiles and regiospecific stereospecific arrangements, including saturated-unsaturated-saturated triglyceride enrichment, for use as frying oils, shortenings, cocoa butter replacements, or industrial lubricants.",
    "title": "Tailored oils",
    "abstract": "Recombinant DNA techniques are used to produce oleaginous recombinant cells that produce triglyceride oils having desired fatty acid profiles and regiospecific or stereospecific profiles. Genes manipulated include those encoding stearoyl-ACP desturase, delta 12 fatty acid desaturase, acyl-ACP thioesterase, ketoacyl-ACP synthase, and lysophosphatidic acid acyltransferase. The oil produced can have enhanced oxidative or thermal stability, or can be useful as a frying oil, shortening, roll-in shortening, tempering fat, cocoa butter replacement, as a lubricant, or as a feedstock for various chemical processes. The fatty acid profile can be enriched in midchain profiles or the oil can be enriched in triglycerides of the saturated-unsatturated-saturated type.",
    "domain": "C07"
  },
  {
    "statement_id": "RN283",
    "patent_id": "9296816",
    "claim": "A diabody molecule comprising two polypeptide chains that associate to form at least two epitope binding sites and are covalently linked through non-peptide bond covalent bonds between cysteine residues within each polypeptide chain, wherein the molecule further comprises an Fc region to confer antibody-like effector functionality.",
    "title": "Covalent diabodies and uses thereof",
    "abstract": "The present invention is directed to diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers. The diabody molecules of the invention comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens. Additionally, the antigens may be from the same or different molecules. The individual polypeptide chains of the diabody molecule may be covalently bound through non-peptide bond covalent bonds, such as, but not limited to, disulfide bonding of cysteine residues located within each polypeptide chain. In particular embodiments, the diabody molecules of the present invention further comprise an Fc region, which allows antibody-like functionality to engineered into the molecule.",
    "domain": "C07"
  },
  {
    "statement_id": "RN284",
    "patent_id": "9677062",
    "claim": "Soluble neutral active hyaluronidase glycoproteins (sHASEGPs) comprising asparagine-linked sugar moieties required for functional neutral active hyaluronidase activity, combined with Factor VIII compositions, wherein pegylated or sialylated forms of sHASEGPs facilitate subcutaneous administration of Factor VIII by degrading hyaluronan in the extracellular matrix to enhance drug dispersion and bioavailability.",
    "title": "Hyaluronidase and factor VIII compositions",
    "abstract": "Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided.",
    "domain": "C07"
  },
  {
    "statement_id": "RN285",
    "patent_id": "9192645",
    "claim": "A combination therapy composition comprising triciribine and bortezomib, wherein the combination exhibits synergistic anticancer activity against tumors and abnormal cell proliferation disorders while demonstrating reduced toxicity compared to either agent administered alone.",
    "title": "Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof",
    "abstract": "This application relates to combination therapies including triciribine and related compounds and bortezomib and derivatives thereof analogs and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.",
    "domain": "C07"
  },
  {
    "statement_id": "RN286",
    "patent_id": "10815525",
    "claim": "Barcoded oligonucleotides bound to gel beads are used to simultaneously characterize multiple analyte types—including cell surface proteins, intracellular proteins, genomic DNA, and RNA—within a single workflow by tagging each analyte with a unique barcode identifier enabling downstream sequencing-based analyte characterization.",
    "title": "Methods and systems for processing polynucleotides",
    "abstract": "The present disclosure provides compositions, methods, systems, and devices for polynucleotide processing and analyte characterization. Such polynucleotide processing may be useful for a variety of applications, including analyte characterization by polynucleotide sequencing. The compositions, methods, systems, and devices disclosed herein generally describe barcoded oligonucleotides, which can be bound to a bead, such as a gel bead, useful for characterizing one or more analytes including, for example, protein (e.g., cell surface or intracellular proteins), genomic DNA, and RNA (e.g., mRNA or CRISPR guide RNAs). Also described herein, are barcoded labelling agents and oligonucleotide molecules useful for “tagging” analytes for characterization.",
    "domain": "C07"
  },
  {
    "statement_id": "RN287",
    "patent_id": "11253551",
    "claim": "Cardiosphere-derived cells (CDCs) and exosomes secreted by CDCs, when administered to subjects with heart failure with preserved ejection fraction (HFpEF), improve left ventricular diastolic relaxation, reduce LV end-diastolic pressure, decrease lung congestion, lower arrhythmia risk, and enhance survival, demonstrating therapeutic efficacy in a condition unresponsive to standard heart failure therapies.",
    "title": "Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction",
    "abstract": "Heart failure with preserved ejection fraction (HFpEF) is a disease condition characterized by heart failure (HF) signs and symptoms, but with normal or near normal left ventricular ejection fraction (LVEF) and is not responsive to standard therapy for treatment of HF. Described herein are compositions and methods related to use of cardiosphere derived cells (CDCs) and their exosomes to improve left ventricular structure, function and overall outcome. Administration of CDCs led to improved LV relaxation, lower LV end-diastolic pressure, decreased lung congestion and enhanced survival. Lower risk of arrhythmias in HFpEF was also observed following CDC administration. Improvement of diastolic dysfunction following administration of CDC-derived exosomes was observed, along with decreased mortality. In view of these salutary effects, CDCs and CDC-derived exosomes are beneficial in the treatment of HFpEF.",
    "domain": "C12"
  },
  {
    "statement_id": "RN288",
    "patent_id": "9081020",
    "claim": "A method for selecting thermostabilized membrane protein mutants by exposing candidate mutants within a membrane-containing composition to a membrane-destabilizing agent at a concentration sufficient to destabilize the parent membrane protein in-situ, then selecting mutants that retain structural integrity or biological activity compared to the destabilized parent protein.",
    "title": "Mutant proteins and methods for selecting them",
    "abstract": "A method for selecting a membrane protein with increased stability, the method comprising: a) providing one or more mutants of a parent membrane protein in a membrane-containing composition, wherein the one or more mutants are exposed to an amount of a membrane destabilizing agent which is effective to destabilize the parent membrane protein in-situ, b) determining whether the or each mutant membrane protein has increased stability with respect to its structure and/or a biological activity compared to the stability of the parent membrane protein with respect to its structure and/or the same biological activity, and c) selecting the one or more mutants which have increased stability compared to the stability of the parent membrane protein.",
    "domain": "C12"
  },
  {
    "statement_id": "RN289",
    "patent_id": "10865452",
    "claim": "A prostate cancer prognostic system comprising defined sets of gene transcript sequences whose expression changes correlate with recurrent versus non-recurrent prostate cancer, together with corresponding polynucleotide probes and primers deployable in solution or array format to classify prostate cancer tissue disease states.",
    "title": "Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer",
    "abstract": "A system for expression-based discrimination of distinct clinical disease states in prostate cancer is provided that is based on the identification of sets of gene transcripts, which are characterized in that changes in expression of each gene transcript within a set of gene transcripts can be correlated with recurrent or non-recurrent prostate cancer. The Prostate Cancer Prognostic system provides for sets of “prostate cancer prognostic” target sequences and further provides for combinations of polynucleotide probes and primers derived there from. These combinations of polynucleotide probes can be provided in solution or as an array. The combination of probes and the arrays can be used for diagnosis. The invention further provides further methods of classifying prostate cancer tissue.",
    "domain": "C12"
  },
  {
    "statement_id": "RN290",
    "patent_id": "10472419",
    "claim": "Antibody molecules that specifically bind to TIM-3 (T-cell immunoglobulin and mucin-domain containing-3) with defined heavy and light chain complementarity-determining regions, capable of modulating TIM-3-mediated immune checkpoint signaling for use in treating cancer or infectious diseases.",
    "title": "Antibody molecules to TIM-3 and uses thereof",
    "abstract": "Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.",
    "domain": "C07"
  },
  {
    "statement_id": "RN291",
    "patent_id": "7919608",
    "claim": "Expressed Sequence Tags (ESTs) isolated from maize tissue are disclosed as molecular tools for isolating novel plant genes and promoters, identifying and mapping genes involved in developmental and metabolic pathways, and enabling sequence homology analyses for screening agronomic traits.",
    "title": "Nucleic acid molecules and other molecules associated with plants",
    "abstract": "Expressed Sequence Tags (ESTs) isolated from maize are disclosed. The ESTs provide a unique molecular tool for the targeting and isolation of novel genes for plant protection and improvement. The disclosed ESTs have utility in the development of new strategies for understanding critical plant developmental and metabolic pathways. The disclosed ESTs have particular utility in isolating genes and promoters, identifying and mapping the genes involved in developmental and metabolic pathways, and determining gene function. Sequence homology analyses using the ESTs provided in the present invention, will result in more efficient gene screening for desirable agronomic traits. An expanding database of these select pieces of the plant genomics puzzle will quickly expand the knowledge necessary for subsequent functional validation, a key limitation in current plant biotechnology efforts.",
    "domain": "C07"
  },
  {
    "statement_id": "RN292",
    "patent_id": "9617309",
    "claim": "A stapled peptide cross-link formed by olefin metathesis between a proline derivative bearing an alkenyl side chain and another amino acid derivative bearing an alkenyl side chain, where the proline derivative functions as a strong nucleator of alpha-helix formation and the resulting macrocyclic staple stabilizes helical secondary structure.",
    "title": "Proline-locked stapled peptides and uses thereof",
    "abstract": "The present invention provides a new type of alpha-helix nucleating cross-link (“staple”) formed by olefin metathesis of a proline derivative with an alkenyl side chain and another amino acid derivative with an alkenyl side chain. The proline derivatives as described herein have been found to be strong nucleators of alpha-helix formation. The invention also provides moieties for shielding the free amide N—H's at the N-terminus of an alpha-helix, thereby further stabilizing the helix. The proline derivatives, precursors prior to cross-linking, and the cross-linked peptides are provided as well as methods of using and preparing these compounds and peptides.",
    "domain": "C07"
  },
  {
    "statement_id": "RN293",
    "patent_id": "8012482",
    "claim": "Humanized antibodies that specifically bind TGF-beta, wherein murine anti-TGF-beta antibody complementarity-determining regions are grafted onto human antibody framework regions to produce antibodies with reduced immunogenicity while retaining binding specificity and affinity for TGF-beta, suitable for treating TGF-beta-mediated disorders including cancer.",
    "title": "Humanized anti-TGF-beta antibodies",
    "abstract": "Humanized anti-TGF-beta antibodies are provided, as well as methods for their preparation and use, including methods for treating TGF-beta disorders, for example, cancer. Also provided are articles of manufacture designed for various uses that contain the humanized antibodies.",
    "domain": "A61"
  },
  {
    "statement_id": "RN294",
    "patent_id": "8034329",
    "claim": "Human umbilical cord tissue-derived cells, when administered to a patient, promote repair and regeneration of diseased or damaged renal tissue, providing a cell-based therapeutic approach to treating kidney disease that leverages the unique regenerative properties of umbilical cord tissue-derived cells rather than embryonic or adult stem cell sources.",
    "title": "Repair and regeneration of renal tissue using human umbilical cord tissue-derived cells",
    "abstract": "Methods for treating a patient having a disease or damage to at least one kidney are provided. The methods comprise administering cells obtained from human umbilical cord tissue, or administering pharmaceutical compositions comprising such cells or prepared from such cells. When administered, the cells promote and support the repair and regeneration of the diseased or damaged kidney tissue in the patient. Pharmaceutical compositions for use in the inventive methods, as well as kits for practicing the methods are also provided.",
    "domain": "A61"
  },
  {
    "statement_id": "RN295",
    "patent_id": "9284409",
    "claim": "A medical endoprosthesis having a surface comprising a catalytic material with a non-fouling material covalently attached thereto, wherein the non-fouling material is releasably bound to the surface via a cleavable chemical bond that allows controlled release of the non-fouling material from the device surface.",
    "title": "Endoprosthesis having a non-fouling surface",
    "abstract": "In embodiments, medical devices have a surface that includes a catalytic material, and a non-fouling material attached to the surface. The non-fouling material can be released from the surface, for example, by cleavage of a bond connecting the material to the surface. The bond can be a chemical bond, such as a covalent bond.",
    "domain": "C07"
  },
  {
    "statement_id": "RN296",
    "patent_id": "11253860",
    "claim": "A digital microfluidic fluid application and extraction interface device comprising a waste reservoir with a fluid trap and a transfer conduit extending through the waste reservoir, wherein the transfer conduit doubles back on itself to hold a fluid sample while allowing excess fluid to pass from the transfer conduit into the waste reservoir where it is trapped within the waste chamber.",
    "title": "Digital microfluidic devices and methods",
    "abstract": "Digital microfluidic (DMF) apparatuses, systems, devices and associated fluid manipulation and extraction devices, and methods of using them are presented. The devices may be useful for analysis of clinical, laboratory, chemical, or biological samples. A fluid application and extraction interface device may include a waste reservoir with a fluid trap and a transfer conduit extending through the waste reservoir so that fluid may pass from the transfer conduit into the waste reservoir and be trapped within the waste chamber. A transfer conduit may be configured to double back on itself and to hold a fluid sample. A DMF apparatus may be configured to hold and process large sample volumes.",
    "domain": "C07"
  },
  {
    "statement_id": "RN297",
    "patent_id": "10298293",
    "claim": "A housing configured to connect with a utility structure that contains two separate wireless devices, each coupled to respective antennas extending outside the housing, with the wireless devices coupled to each other to enable communication relay functionality mounted on utility infrastructure.",
    "title": "Apparatus of communication utilizing wireless network devices",
    "abstract": "Aspects of the subject disclosure may include, for example a housing defining an open volume therein where the housing includes a connection structure for connecting with a utility structure, a first wireless device contained in the housing where the first wireless device is coupled with a first antenna extending outside of the housing, and a second wireless device contained in the housing where the second wireless device is coupled with a second antenna extending outside of the housing. The first and second wireless devices can be coupled to each other. Other embodiments are disclosed.",
    "domain": "A61"
  },
  {
    "statement_id": "RN298",
    "patent_id": "8550694",
    "claim": "A mixing cartridge comprising a body structure defining a cavity with upper and lower portions, wherein a rotatable member extends along a horizontal axis in the upper portion of the cavity and one or more protrusions extend outward from the rotatable member into the lower portion of the cavity to mix fluidic material disposed therein.",
    "title": "Mixing cartridges, mixing stations, and related kits, systems, and methods",
    "abstract": "Cartridges useful for mixing materials, such as fluidic materials are provided. A cartridge typically includes a body structure having surfaces that define a cavity with upper and lower portions. A rotatable member generally extends along a horizontal axis in the upper portion of the cavity. One or more protrusions typically extend outward from the rotatable member and into the lower portion of the cavity, and are configured to mix the material when the material is disposed in the cavity. Related mixing stations, systems, kits, and methods are also provided.",
    "domain": "C12"
  },
  {
    "statement_id": "RN299",
    "patent_id": "9904535",
    "claim": "A first network device receives software from a second network device, applies a digital signature to the software to indicate receipt, and forwards the digitally-signed software to a third network device, enabling tracking of software distribution across a chain of network devices.",
    "title": "Method and apparatus for distributing software",
    "abstract": "Aspects of the subject disclosure may include, for example, a first network device receiving from a second network device a software, the first network device adjusting operations at the first network device according to the software, the first network device providing a digital signature to the software to generate an adjusted software where the digital signature indicates that the first network device has received the software, and the first network device transmitting, to a third network device, the adjusted software. Other embodiments are disclosed.",
    "domain": "C12"
  },
  {
    "statement_id": "RN300",
    "patent_id": "9620105",
    "claim": "An audio processing system that analyzes incoming audio input to classify it as either music or speech, generates an acoustic fingerprint for audio portions classified as music, and identifies speech utterance endpoints for audio portions classified as speech, thereby applying distinct recognition pathways based on audio content type.",
    "title": "Analyzing audio input for efficient speech and music recognition",
    "abstract": "Systems and processes for analyzing audio input for efficient speech and music recognition are provided. In one example process, an audio input can be received. A determination can be made as to whether the audio input includes music. In addition, a determination can be made as to whether the audio input includes speech. In response to determining that the audio input includes music, an acoustic fingerprint representing a portion of the audio input that includes music is generated. In response to determining that the audio input includes speech rather than music, an end-point of a speech utterance of the audio input is identified.",
    "domain": "C12"
  }
]